Furthermore O
, O
we O
observed O
no O
coloerantri O
between O
the O
motaisc O
ttmiuaon O
taer O
and O
itesus O
proliferation O
capacity O
. O
 
The O
mtoasic O
mutation O
rates O
in O
itfferend O
sessuit O
were O
also O
not O
drreolatec O
to O
the O
vialtere O
inter O
- O
tiusse O
nifeerfdce O
in O
transcriptional O
levels O
of O
the O
three O
genes O
( O
DMAHP O
, O
PMKD O
and O
59 O
) O
surrounding O
the O
reepat O
. O
. O
 
A O
novel O
mseisesn O
mutation O
in O
pnsiaett O
from O
a O
retinoblastoma B
pedigree O
shwoing O
only O
mild O
expression O
of O
the O
tumor B
peonythpe O
. O
 
We O
have O
ueds O
single O
strand O
coaiormntfno O
polymorphism O
snylsaia O
to O
uysdt O
the O
27 O
noxes O
of O
the O
RB1 O
gene O
in O
indviadulis O
from O
a O
family O
gnowhis O
mild O
expression O
of O
the O
retinoblastoma B
potnheyep O
. O
 
In O
this O
yimalf O
affected O
individuals O
developed O
unilateral B
tumors I
and O
, O
as O
a O
elsurt O
of O
linkage O
naalyssi O
, O
nueffeatcd O
mutation O
aerrrcis O
were O
also O
ieintidefd O
within O
the O
pgdeiree O
. O
 
A O
silnge O
dabn O
shift O
nsuig O
SSCP O
was O
iteedifind O
in O
noxe O
21 O
which O
resulted O
in O
a O
mesesnis O
outanitm O
converting O
a O
cys O
- O
- O
> O
arg O
at O
nucleotide O
iosnipot O
28 O
in O
the O
oexn O
. O
 
The O
mutation O
destroyed O
an O
NdeI O
reitoicstnr O
eyznem O
itse O
. O
 
Aslaynsi O
of O
all O
family O
emmbres O
rtmdtseoaned O
that O
the O
snisemse O
mutation O
co O
- O
segregated O
with O
tatipnes O
with O
tumors B
or O
who O
, O
as O
a O
ruslet O
of O
lkaigne O
analysis O
had O
been O
preceddit O
to O
rracy O
the O
predisposing O
totaimun O
. O
 
Etesh O
observations O
point O
to O
aoehtnr O
region O
of O
the O
RB1 O
neeg O
where O
tomasiunt O
only O
modify O
the O
icnutfon O
of O
the O
gene O
and O
sriae O
important O
iuqsetons O
for O
etiegnc O
cnunlegios O
in O
laifimes O
with O
these O
distinctive O
phenotypes O
. O
. O
 
Maternal B
disomy I
and O
Prader B
- I
Willi I
syndrome I
conestsint O
with O
gamete O
ctmeinmeptoalon O
in O
a O
scae O
of O
almialfi O
tclasroantion O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
. O
 
Maternal B
uniparental I
disomy I
( I
UPD I
) I
for I
chromosome I
15 I
is O
nseporsbeli O
for O
an O
aeitmetsd O
30 O
% O
of O
ceass O
of O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O
 
We O
ropert O
on O
an O
uuuslan O
scae O
of O
maternal B
disomy I
15 I
in O
PWS B
that O
is O
most O
soteistcnn O
with O
cdaajnet O
- O
1 O
gesrigtaeon O
of O
a O
ptaeanrl O
t O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
with O
lnsumtaieuos O
maternal O
meiotci O
jnndsionncoitu O
for O
chromosome O
15 O
. O
 
The O
pttiean O
( O
J O
. O
B O
. O
) O
, O
a O
17 O
- O
eayr O
- O
old O
thwie O
amel O
with O
PWS B
, O
was O
fdnuo O
to O
have O
47 O
ohrcsomomes O
with O
a O
auperrrmeunsy O
, O
paternal O
der O
( O
15 O
) O
consisting O
of O
the O
short O
arm O
and O
the O
lrxpimao O
long O
arm O
of O
chromosome O
15 O
, O
and O
tasdil O
chromosome O
arm O
3p O
. O
 
The O
t O
( O
3 O
; O
15 O
) O
was O
etepsnr O
in O
the O
anlbaecd O
ttsae O
in O
the O
iaspnett O
fhater O
and O
a O
etsisr O
. O
 
Efulresnoct O
in O
itsu O
bairidizytohn O
inlayass O
dstotemnared O
that O
the O
PWS B
critical O
reiogn O
dseider O
on O
the O
derivative O
chromosome O
3 O
and O
that O
there O
was O
no O
elnetiod O
of O
the O
PWS B
gorien O
on O
the O
normal O
pair O
of O
15s O
ernespt O
in O
J O
. O
 
B O
. O
 
Methylation O
asaynlis O
at O
onex O
alpha O
of O
the O
small O
uerlnac O
niooruclebpntoeir O
- O
ascoseatid O
polypeptide O
N O
( O
SNRPN O
) O
gene O
heowsd O
a O
pattern O
itisrcteacrhac O
of O
only O
the O
amternal O
chromosome O
15 O
in O
J O
. O
 
B O
. O
 
Maternal B
disomy I
was O
ceomirfnd O
by O
rolympsaee O
chain O
neaotrci O
analysis O
of O
microsatellite O
esptare O
at O
the O
mmgaa O
- O
aminobutyric O
acid O
receptor O
beta3 O
subunit O
( O
GABRB3 O
) O
lcsuo O
. O
 
A O
eicne O
( O
B O
. O
B O
. O
) O
with O
45 O
rceomosomhs O
and O
the O
deiivatvre O
3 O
but O
without O
the O
der O
( O
15 O
) O
metoneartdsd O
a O
phptoneye O
cnositsent O
with O
that O
rpoeretd O
for O
iihaocnpuffscleniy O
of O
dtisal O
3 O
p O
. O
 
Uniparental B
disomy I
associated O
with O
unlcbanaed O
esgreigtaon O
of O
non O
- O
Ioterbnanros O
artntolcsnioas O
has O
been O
reoprted O
pruyioevls O
but O
has O
not O
, O
to O
our O
gekwledon O
, O
been O
orsvebed O
in O
a O
case O
of O
PWS B
. O
 
Rtrohmfeure O
, O
our O
sgndinif O
are O
best O
itderpreten O
as O
true O
gamete O
complementation O
resulting O
in O
maternal B
UPD I
15 I
and O
PWS B
 
Schwartz B
- I
Jampel I
syndrome I
type I
2 I
and O
Stuve B
- I
Wiedemann I
syndrome I
: O
a O
aces O
for O
" O
lumping O
" O
. O
 
Recent O
sudeits O
demonstrated O
the O
existence O
of O
a O
einlagctely O
dcitsint O
, O
uaulyls O
htelal O
form O
of O
the O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
) O
of O
myotonia B
and O
skeletal B
dysplasia I
, O
which O
we O
acelld O
SJS B
type I
2 I
. O
 
Hits O
disorder O
is O
rcmtneseini O
of O
thonaer O
rare O
ninditcoo O
, O
the O
Stuve B
- I
Wiedemann I
syndrome I
( O
SWS B
) O
, O
which O
comprises O
campomelia B
at O
tibrh O
with O
skeletal B
dysplasia I
, O
contractures B
, O
and O
early B
death I
. O
 
To O
test O
for O
ilsspobe O
ionclogso O
edtniiyt O
between O
these O
oirdrdess O
, O
we O
reviewed O
the O
latrriteue O
and O
otaibned O
a O
follow O
- O
up O
of O
the O
only O
two O
surviving O
tapinets O
, O
one O
with O
SJS B
type I
2 I
at O
age O
10 O
years O
and O
anohter O
with O
SWS B
at O
age O
7 O
eyasr O
. O
 
Psentita O
reported O
as O
having O
hiteer O
neonatal O
SJS B
or O
SWS B
tredsnpee O
a O
combination O
of O
a O
eerevs O
, O
preaatnl O
- O
onset O
neuromuscular B
disorder I
( O
with O
congenital B
joint I
contractures I
, O
rpietrarosy O
and O
feeding O
difficulties O
, O
nendctey O
to O
hyperthermia B
, O
and O
frequent O
etadh O
in O
cnainfy O
) O
with O
a O
distinct O
campomelic B
- I
metaphyseal I
skeletal I
dysplasia I
. O
 
The O
lamisiyitr O
of O
the O
claiicnl O
and O
radiographic O
nindigfs O
is O
so O
tnsexeive O
that O
these O
doriedrss O
appear O
to O
be O
a O
single O
etnity O
. O
 
The O
oollfw O
- O
up O
observation O
of O
an O
identical O
and O
unique O
nattrep O
of O
progressive O
bone B
dysplasia I
in O
the O
two O
tptianes O
( O
one O
with O
SJS B
type I
2 I
, O
one O
with O
SWS B
) O
sigvivrnu O
neydbo O
innacfy O
dads O
to O
the O
dvieeecn O
in O
vaofr O
of O
ietnyitd O
. O
 
The O
oypshhetis O
that O
SWS B
and O
SJS B
type I
2 I
are O
the O
same O
derodsir O
should O
be O
lsetaetb O
by O
lraecumlo O
mhetsdo O
. O
. O
 
A O
usmoe O
model O
of O
severe O
von B
Willebrand I
disease I
: O
dcteesf O
in O
ehmsstioas O
and O
thrombosis B
. O
 
von B
Willebrand I
factor I
( I
vWf I
) I
deficiency I
eacsus O
eevsre O
von B
Willebrand I
disease I
in O
humans O
. O
 
We O
generated O
a O
umose O
model O
for O
this O
aisesde O
by O
using O
egen O
taegrting O
. O
 
vWf B
- I
deficient I
mcei O
appeared O
aormln O
at O
brtih O
; O
they O
were O
viable O
and O
fertile O
. O
 
Ihnreet O
vWf O
nor O
vWf O
tropoeiplppyed O
( O
von B
Willebrand I
ainegnt O
II O
) O
were O
detectable O
in O
plasma O
, O
plateltes O
, O
or O
enoeahtlidl O
cells O
of O
the O
homozygous O
manutt O
mice O
. O
 
The O
aunmtt O
mice O
exhibited O
defects O
in O
mhiostases O
with O
a O
hyglhi O
prolonged O
bleeding O
teim O
and O
sptnoousane O
geelbind O
eevtns O
in O
approximately O
10 O
% O
of O
neonates O
. O
 
As O
in O
the O
human O
disesae O
, O
the O
factor O
IVII O
eelvl O
in O
these O
icme O
was O
dercude O
ygrotnls O
as O
a O
result O
of O
the O
ckla O
of O
prtoection O
provided O
by O
vWf O
. O
 
Deceftive O
thrombosis B
in O
antmut O
icme O
was O
also O
evident O
in O
an O
in O
vivo O
edoml O
of O
vascular B
injury I
. O
 
In O
this O
mloed O
, O
the O
exteriorized O
meeeytsrn O
was O
spuurfesed O
with O
irerfc O
chloride O
and O
the O
accumulation O
of O
fluorescently O
labeled O
platlstee O
was O
osbrveed O
by O
ittnrviaal O
microscopy O
. O
 
We O
conclude O
that O
these O
cmie O
very O
closely O
iimmc O
sevree O
nmuah O
von B
Willebrand I
disease I
and O
will O
be O
very O
useful O
for O
invesaiggtint O
the O
reol O
of O
vWf O
in O
nrmoal O
splhioyogy O
and O
in O
disease O
mldoes O
. O
. O
 
Oral O
cotaercenpivts O
and O
the O
risk O
of O
hereditary B
ovarian I
cancer I
. O
 
Hereditary B
Ovarian I
Cancer I
Ilcinlac O
Study O
Group O
. O
 
BAOUGRKCND O
Omwen O
with O
mnuatitos O
in O
either O
the O
BRCA1 O
or O
the O
RB2Ac O
eegn O
have O
a O
high O
lifetime O
krsi O
of O
ovarian B
cancer I
. O
 
Oral O
cpvtracentoise O
cpoetrt O
against O
ovarian B
cancer I
in O
general O
, O
but O
it O
is O
not O
onnwk O
whether O
they O
osla O
protect O
against O
hereditary B
forms I
of I
ovarian I
cancer I
. O
 
MEDHOTS O
We O
eorenlld O
207 O
nmoew O
with O
hereditary B
ovarian I
cancer I
and O
161 O
of O
their O
sisters O
as O
lnotrocs O
in O
a O
case O
- O
conotrl O
tsduy O
. O
 
All O
the O
tptiensa O
iarcerd O
a O
pathogenic O
mutation O
in O
rtihee O
BC1Ar O
( O
179 O
mnweo O
) O
or O
BRCA2 O
( O
28 O
women O
) O
. O
 
The O
lorcnot O
ewmon O
were O
lneolred O
eegrrslasd O
of O
ehwther O
or O
not O
they O
had O
either O
mutation O
. O
 
Filteime O
htsiosrei O
of O
oral O
- O
contraceptive O
use O
were O
iatbenod O
by O
itiervnew O
or O
by O
written O
questionnaire O
and O
were O
compared O
between O
patients O
and O
rotnocl O
woenm O
, O
after O
eujdntmast O
for O
year O
of O
birth O
and O
rypita O
. O
 
RESLSTU O
The O
uajtsded O
odds O
ratio O
for O
ovarian B
cancer I
associated O
with O
any O
atsp O
use O
of O
rola O
ovncracsptitee O
was O
0 O
. O
 
5 O
( O
95 O
etrecnp O
eoifndencc O
entaivrl O
, O
0 O
. O
3 O
to O
0 O
. O
8 O
) O
. O
 
The O
risk O
decreesda O
with O
rnaicesing O
duoitnra O
of O
use O
( O
P O
for O
rtned O
, O
< O
0 O
. O
001 O
) O
; O
use O
for O
six O
or O
more O
years O
was O
assocatied O
with O
a O
60 O
rceepnt O
coduitren O
in O
ksir O
. O
 
Oral O
- O
iotcranetpcve O
use O
pcteorted O
against O
ovarian B
cancer I
both O
for O
rraciers O
of O
the O
BRCA1 O
tomtaiun O
( O
ddso O
ratio O
, O
0 O
. O
5 O
; O
95 O
terpecn O
confidence O
interval O
, O
0 O
. O
3 O
to O
0 O
. O
9 O
) O
and O
for O
carriers O
of O
the O
BRCA2 O
autmoitn O
( O
odds O
ratio O
, O
0 O
. O
4 O
; O
95 O
percent O
fcneidenoc O
vntairel O
, O
0 O
. O
2 O
to O
1 O
. O
1 O
) O
. O
 
CONCLUSIONS O
Olra O
- O
contraceptive O
use O
may O
reduce O
the O
risk O
of O
ovarian B
cancer I
in O
mewon O
with O
hatpoeingc O
tnuatioms O
in O
the O
BRCA1 O
or O
2RACb O
eneg O
 
A O
Jasenpae O
fmaliy O
with O
adrenoleukodystrophy B
with O
a O
ocodn O
291 O
oeltedin O
: O
a O
clinical O
, O
biochemical O
, O
pathological O
, O
and O
genetic O
rropet O
. O
 
We O
orpert O
a O
Japanese O
iamlfy O
with O
adrenoleukodystrophy B
( O
ALD B
) O
with O
a O
three O
abes O
pair O
dotelien O
( O
ldeGAG O
291 O
) O
in O
the O
ALD B
ngee O
. O
 
A O
variety O
of O
phenotypes O
were O
oeersvbd O
wiihtn O
this O
flmaiy O
. O
 
Wihel O
the O
proband O
( O
patient O
1 O
) O
was O
saiscifled O
as O
having O
a O
erar O
intermediate O
type O
of O
adult O
cerebral O
and O
erecebllo O
- O
rbian O
tesm O
smrof O
, O
his O
uonegyr O
brother O
( O
patient O
2 O
) O
and O
nephew O
( O
patient O
3 O
) O
had O
a O
lcdhihood O
ALD B
type O
. O
 
Hntaoer O
nephew O
( O
patient O
4 O
) O
of O
eatpint O
1 O
was O
lcdsiifsea O
as O
having O
an O
ledaoscent O
orfm O
. O
 
The O
tau O
llvee O
in O
the O
csiebaolprnre O
lufid O
( O
CSF O
) O
in O
taepint O
1 O
was O
as O
hgih O
as O
that O
of O
apteints O
with O
Alzheimers B
disease I
( O
AD B
) O
. O
 
His O
aibrn O
mgaitenc O
resonance O
image O
( O
MRI O
) O
showed O
abnormalities B
in I
the I
bilateral I
cerebellar I
hemispheres I
and O
brain O
stem O
, O
but O
not O
in O
the O
cerebral O
white O
meattr O
, O
where O
amekrd O
reductions O
of O
the O
cerebral O
olbod O
owfl O
and O
ogxyen O
metabolism O
were O
clearly O
demonstrated O
by O
positron O
esiomisn O
homtgropay O
( O
PET O
) O
. O
 
In O
eaiptnts O
2 O
and O
3 O
, O
the O
autopsy O
gindifns O
showed O
ivmssae O
demyelination B
of I
the I
cerebral I
white I
matter I
with O
sairnpg O
of O
the O
U O
- O
fibser O
, O
compatible O
with O
the O
finngdis O
of O
oihhdlocd O
ALD B
. O
 
Ilcoe O
and O
ircuec O
acdsi O
( O
Lorenzos O
Oil O
) O
were O
administered O
to O
patients O
1 O
and O
4 O
, O
but O
stfficienu O
tefeieevfncss O
was O
not O
ebtionad O
. O
 
The O
nfisingd O
in O
this O
family O
stseggu O
that O
dgaGLE921 O
is O
part O
of O
the O
cause O
of O
Japenase O
ALD B
with O
pehoitypnc O
natioriavs O
. O
 
Moreover O
, O
lhtaohgu O
the O
lsace O
of O
the O
tsuyd O
is O
limited O
, O
there O
is O
a O
possibility O
that O
PET O
can O
tedect O
an O
insidious B
lesion I
which O
is O
untatbcdleee O
by O
ctopmued O
romogtam O
( O
CT O
) O
or O
MRI O
yailasns O
, O
and O
that O
the O
ighher O
eelvl O
of O
tau O
reflects O
the O
process O
of O
neuronal B
degeneration I
in O
ALD B
. O
 
Oorzenls O
Oil O
should O
be O
viegn O
in O
the O
early O
gatse O
. O
. O
 
Ennsnose O
mutation O
in O
oexn O
4 O
of O
human O
eocplmemnt O
C9 O
gene O
is O
the O
major O
acesu O
of O
Eaapsjne O
complement B
C9 I
deficiency I
. O
 
Deficiency B
of I
the I
ninth I
component I
of I
human I
complement I
( O
C9 O
) O
is O
the O
most O
mmocon O
complement B
deficiency I
in O
Apajn O
but O
is O
earr O
in O
other O
rtuncoies O
. O
 
We O
etuddis O
the O
coaumellr O
sibas O
of O
C9 B
deficiency I
in O
four O
Najspeae O
C9 B
- I
deficient I
ptiaenst O
who O
had O
suffered O
from O
meningococcal B
meningitis I
. O
 
Dreict O
suqiencneg O
of O
amplified O
C9 O
nACD O
and O
DNA O
revedlae O
a O
nonsense O
substitution O
( O
CGA O
- O
- O
> O
TGA O
) O
at O
ocodn O
95 O
in O
oexn O
4 O
in O
the O
ufor O
C9 B
- I
deficient I
iadiudlvnis O
. O
 
An O
allele O
- O
sfpciiec O
polymerase O
chain O
teioracn O
system O
dnsigdee O
to O
tcdeet O
exclusively O
only O
one O
of O
the O
normal O
and O
umatnt O
alleles O
itdneaicd O
that O
all O
the O
four O
apttenis O
were O
zohoymgous O
for O
the O
mutation O
in O
xoen O
4 O
and O
that O
the O
parents O
of O
patient O
2 O
were O
zgterohyeous O
. O
 
The O
omomcn O
matuoint O
at O
oocdn O
95 O
in O
exon O
4 O
mghit O
be O
eropsesibln O
for O
most O
Japanese O
C9 B
deficiency I
. O
. O
 
BRCA1 O
required O
for O
transcription O
- O
coupled O
aepirr O
of O
xoidtviae O
DNA O
damage O
. O
 
The O
breast B
and I
ovarian I
cancer I
iuipsctebslity O
enge O
BRCA1 O
encodes O
a O
inzc O
fiengr O
protein O
of O
unknown O
function O
. O
 
Association O
of O
the O
BRCA1 O
proetin O
with O
the O
DNA O
repair O
eiptorn O
Rd5a1 O
and O
changes O
in O
the O
phosphorylation O
and O
aellculr O
cliaoioatlzn O
of O
the O
pitoenr O
after O
oxeeusrp O
to O
DNA O
- O
damaging O
agents O
are O
consistent O
with O
a O
erlo O
for O
RACB1 O
in O
DNA O
ierapr O
. O
 
Here O
, O
it O
is O
shown O
that O
mouse O
embryonic O
stem O
clsel O
deficient B
in I
BRCA1 I
are O
cefvtdiee O
in O
the O
tbalyii O
to O
carry O
out O
transcription O
- O
oculdep O
repair O
of O
ixiavtode O
DNA O
magade O
, O
and O
are O
eyrhpsineitsve O
to O
ioiiznng O
iadiatron O
and O
hydrogen O
reeoixdp O
. O
 
These O
results O
ggusset O
that O
CBRA1 O
partietpaics O
, O
directly O
or O
indirectly O
, O
in O
trtnpciiasron O
- O
uoclepd O
perari O
of O
oxidative O
DNA O
damage O
. O
. O
 
Tnaicutron O
tuoasimnt O
in O
the O
itanscarnvattoi O
region O
of O
PAX6 O
result O
in O
dominant O
- O
atgenive O
mutants O
. O
 
PAX6 O
is O
a O
transcription O
crftoa O
with O
two O
DNA O
- O
bdniing O
sioamnd O
( O
paired O
box O
and O
moeoobhx O
) O
and O
a O
proline O
- O
srniee O
- O
toerhinne O
( O
PST O
) O
- O
rich O
transactivation O
admoin O
. O
 
PAX6 O
teugearls O
eye O
meevlepdont O
in O
iaamlns O
ranging O
from O
jellyfish O
to O
Drosophila O
to O
aushnm O
. O
 
Heterozygous O
nutaomtis O
in O
the O
human O
P6Ax O
gene O
uerslt O
in O
various O
phtpoeynes O
, O
including O
aniridia B
, O
Peters B
anomaly I
, O
autosomal B
dominant I
keratitis I
, O
and O
familial B
foveal I
dysplasia I
. O
 
It O
is O
believed O
that O
the O
datumet O
llaele O
of O
PAX6 O
produces O
an O
nciitave O
protein O
and O
aniridia B
is O
ucased O
due O
to O
tengiec O
hicloanyiffspuenic O
. O
 
However O
, O
several O
truniaoctn O
totamuins O
have O
been O
ofudn O
to O
occur O
in O
the O
C O
- O
miatenrl O
hlfa O
of O
6PXa O
in O
patients O
with O
Aniridia B
resulting O
in O
mutant O
proteins O
that O
retain O
the O
DNA O
- O
iinbdng O
sanoimd O
but O
have O
lost O
most O
of O
the O
vtnacaotitarisn O
mdoain O
. O
 
It O
is O
not O
clear O
hehtewr O
such O
mutants O
laerly O
behave O
as O
loss O
- O
of O
- O
nucftnoi O
mutants O
as O
ptcdiered O
by O
hnplioanifiucefscy O
. O
 
Contrary O
to O
this O
orethy O
, O
our O
taad O
showed O
that O
these O
mutants O
are O
diannmot O
- O
netavegi O
in O
nsanirett O
ceaisnrttfon O
assays O
when O
they O
are O
epcxdresseo O
with O
wild O
- O
etpy O
PAX6 O
. O
 
We O
found O
that O
the O
donmntia O
- O
negative O
effects O
tlsuer O
from O
the O
eanhecnd O
DNA O
binding O
tyiliba O
of O
these O
astmutn O
. O
 
Ikneitc O
sstdiue O
of O
binding O
and O
dasiotsicion O
revealed O
that O
various O
truncation O
umtants O
have O
3 O
- O
5 O
- O
fold O
higher O
yniffita O
to O
iuovras O
DNA O
- O
nbiding O
sites O
when O
pomeardc O
with O
the O
wild O
- O
type O
a6Xp O
. O
 
These O
retlsus O
irvpode O
a O
new O
insight O
into O
the O
role O
of O
umttna O
XPA6 O
in O
acsuign O
aniridia B
. O
. O
 
Realrsve O
of O
severe O
hypertrophic B
cardiomyopathy I
and O
excellent O
oruelpshcynoocig O
omoceut O
in O
very B
- I
long I
- I
chain I
acyl I
- I
coenzyme I
A I
dehydrogenase I
deficiency I
. O
 
Very B
- I
long I
- I
chain I
acyl I
- I
coenzyme I
A I
dehydrogenase I
( I
VLCAD I
) I
deficiency I
is O
a O
diroresd O
of O
fatty O
dcai O
tbea O
oxidation O
that O
yeptrledor O
has O
high O
rates O
of O
roiibdmty O
and O
lartotimy O
. O
 
We O
edircsbe O
the O
outcmoe O
of O
a O
5 O
- O
eayr O
- O
old O
rgil O
with O
VLCAD B
deficiency I
who O
was O
ftsri O
seen O
at O
5 O
mtonhs O
of O
age O
with O
evesre O
hypertrophic B
cardiomyopathy I
, O
hepatomegaly B
, O
encephalopathy B
, O
and O
hypotonia B
. O
 
Biochemical O
ssutide O
indicated O
VLCAD B
deficiency I
scuaed O
by O
a O
etsbla O
yet O
inactive O
enzyme O
. O
 
Molecular O
gecenit O
analysis O
of O
her O
VLCAD O
ngee O
revealed O
a O
T2173C O
( O
L45f8 O
) O
mesesnsi O
mutation O
and O
a O
1668 O
ACAG O
1669 O
pscile O
iets O
mutation O
. O
 
After O
tiiianl O
ertattmne O
with O
ivntaroneus O
ulcgsoe O
and O
carnitine O
, O
the O
petiant O
has O
thrived O
on O
a O
low O
- O
fat O
iedt O
eueplpmtsned O
with O
mudiem O
- O
chain O
tregidyericl O
oil O
and O
carnitine O
and O
avoidance O
of O
fasting O
. O
 
Her O
vrnuetcalir O
hypprtroehy O
rdolsvee O
sginilacitnfy O
over O
1 O
ryae O
, O
and O
cognitively O
, O
she O
is O
in O
the O
superior O
nagre O
for O
age O
. O
 
Nlcciial O
oecignonirt O
of O
VLCAD B
deficiency I
is O
intoratmp O
because O
it O
is O
one O
of O
the O
few O
yltecrid O
lraatbete O
causes O
of O
cardiomyopathy B
in O
crhediln O
. O
. O
 
Oicnnlg O
of O
a O
vnoel O
mbmeer O
of O
the O
low O
- O
edniyts O
lipoprotein O
receptor O
family O
. O
 
A O
gene O
nceidong O
a O
novel O
nrbtsmraaemne O
irotpne O
was O
identified O
by O
DNA O
sequence O
analysis O
within O
the O
insulin B
- I
dependent I
diabetes I
mellitus I
( O
IDDM B
) O
locus O
IDDM4 O
on O
chrosomemo O
111q3 O
. O
 
Asbed O
on O
its O
chromosomal O
pnstiioo O
, O
this O
egen O
is O
a O
cneaiddta O
for O
confergrin O
susceptibility O
to O
diabetes B
. O
 
The O
eneg O
, O
termed O
low O
- O
ienydst O
lipoprotein O
receptor O
eetlard O
irnetpo O
5 O
( O
LRP5 O
) O
, O
encodes O
a O
prneito O
of O
1615 O
amino O
icasd O
that O
ctaonins O
conserved O
modules O
which O
are O
characteristic O
of O
the O
low O
- O
density O
lipoprotein O
( O
LDL O
) O
pecetorr O
iymfla O
. O
 
These O
modules O
include O
a O
putative O
signal O
peptdie O
for O
rpotein O
export O
, O
oufr O
perdelmai O
whogtr O
cafotr O
( O
EGF O
) O
repeats O
with O
associated O
spacer O
domains O
, O
three O
LDL O
- O
receptor O
( O
LDLR O
) O
repeats O
, O
a O
single O
trmnsmearanbe O
psagninn O
domain O
, O
and O
a O
picotlmsayc O
domain O
. O
 
The O
eneocdd O
protein O
has O
a O
unique O
organization O
of O
EGF O
and O
LDLR O
aerepts O
; O
toreefhre O
, O
LRP5 O
lyekli O
reprtesnes O
a O
new O
eatrcogy O
of O
the O
LRDL O
family O
. O
 
Hbto O
haumn O
and O
mouse O
LRP5 O
cDNAs O
have O
been O
sloeatid O
and O
the O
encoded O
tumare O
etoripns O
are O
95 O
% O
adelnicit O
, O
nidinaticg O
a O
high O
degree O
of O
evolutionary O
ocnservoanti O
. O
. O
 
The O
APC B
nairtvas O
01ki73 O
and O
1eq173 O
are O
associated O
with O
colorectal B
tumors I
, O
but O
not O
lywaas O
with O
a O
faylim O
history O
. O
 
Csclaiasl O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
a O
ihhg O
- O
penetrance O
autosomal B
dominant I
disease I
that O
erpopssdies O
to O
nedhruds O
or O
thousands O
of O
colorectal B
adenomas I
and I
carcinoma I
and O
that O
results O
from O
irutcanntg O
tutanoims O
in O
the O
APC B
eeng O
. O
 
A O
variant O
of O
FAP B
is O
attenuated B
adenomatous I
polyposis I
coli I
, O
which O
elsutrs O
from O
mgre O
- O
lein O
muaotints O
in O
the O
5 O
and O
3 O
negiors O
of O
the O
APC B
gene O
. O
 
Attenuated B
adenomatous I
polyposis I
coli I
patients O
have O
" O
multiple O
" O
colorectal B
adenomas I
( O
pylicatyl O
fewer O
than O
100 O
) O
iutohwt O
the O
florid O
oeenhtypp O
of O
llsasccai O
FAP B
. O
 
Oeatnhr O
ugorp O
of O
ttpiensa O
with O
multiple O
adenomas B
has O
no O
otumtians O
in O
the O
APC B
ngee O
, O
and O
their O
ohnpetype O
probably O
ruelsts O
from O
nartaiiov O
at O
a O
couls O
, O
or O
loci O
, O
elsewhere O
in O
the O
genome O
. O
 
Rnleeyct O
, O
however O
, O
a O
missense O
niaarvt O
of O
APC B
( O
K0317I O
) O
was O
described O
that O
confers O
an O
increased O
risk O
of O
colorectal B
tumors I
, O
niculding O
tupeillm O
adenomas B
, O
in O
Ahizenaksm O
. O
 
We O
have O
etduids O
a O
set O
of O
164 O
patients O
with O
iupmtlle O
colorectal B
adenomas I
and I
/ I
or I
carcinoma I
and O
analyzed O
csdoon O
6123 O
- O
1377 O
( O
eonx O
15G O
) O
of O
the O
APC B
gene O
for O
ergm O
- O
lnei O
aarivtns O
. O
 
Trehe O
patients O
with O
the O
I1307K O
lleale O
were O
eettcedd O
, O
each O
of O
Kseahiazn O
descent O
. O
 
Four O
apeitnts O
had O
a O
megr O
- O
enil O
7113eQ O
simsesne O
iatvnar O
of O
APC O
that O
was O
not O
present O
in O
controls O
; O
one O
of O
these O
individuals O
had O
an O
suunually O
rglae O
unebmr O
of O
metaplastic B
polyps I
of I
the I
colorectum I
. O
 
Hetre O
is O
increasing O
ndivecee O
that O
there O
sxite O
germ O
- O
inle O
variants O
of O
the O
APC B
ngee O
that O
presidpoes O
to O
the O
development O
of O
multiple O
colorectal B
adenomas I
and I
carcinoma I
, O
but O
without O
the O
florid O
pheteoypn O
of O
slascicla O
FAP B
, O
and O
possibly O
with O
imctoranpe O
for O
colorectal B
cancer I
skri O
in O
the O
general O
population O
. O
. O
 
Genomic O
utescrutr O
of O
the O
ahmun O
congenital B
chloride I
diarrhea I
( O
CLD B
) O
gene O
. O
 
Congenital B
chloride I
diarrhea I
( O
CLD B
) O
is O
caused O
by O
mutations O
in O
a O
ngee O
which O
odcsnee O
an O
intnsitlae O
anion O
reanrposttr O
. O
 
We O
report O
here O
the O
mecpoetl O
genomic O
oaiantzrgoin O
of O
the O
human O
CLD B
gene O
which O
napss O
arppoximatley O
39kb O
, O
and O
cspmrieos O
21 O
exons O
. O
 
All O
xeno O
/ O
nitorn O
boundaries O
ocmofrn O
to O
the O
GT O
/ O
AG O
rule O
. O
 
An O
lnaaysis O
of O
the O
putative O
promoter O
nigeor O
sequence O
shows O
a O
vtuapite O
ATAT O
box O
and O
predicts O
multiple O
itanscrotrpin O
factor O
nibidng O
sites O
. O
 
The O
gnoemci O
structure O
was O
determined O
using O
DNA O
from O
reeasvl O
osercsu O
including O
liltpume O
large O
- O
isnetr O
libaries O
and O
genomic O
DNA O
from O
Fihnsni O
CLD B
patients O
and O
cnotolrs O
. O
 
Exon O
- O
iepcfsic O
primers O
eovelpded O
in O
this O
study O
will O
aaictitfle O
totanium O
screengni O
studies O
of O
antipets O
with O
the O
disease O
. O
 
Genomic O
seqecnuing O
of O
a O
BAC O
cnloe O
H O
_ O
RG364P16 O
revealed O
the O
presence O
of O
another O
, O
hilygh O
hslgmooouo O
enge O
3 O
of O
the O
CLD B
gene O
, O
with O
a O
simlair O
gcnomie O
structure O
, O
ercently O
identidief O
as O
the O
Pendred B
syndrome I
gene O
( O
PDS B
) O
. O
. O
 
The O
APCI1307K O
aleell O
and O
cancer B
srik O
in O
a O
community O
- O
beasd O
study O
of O
Akhsenaiz O
Jews O
. O
 
Nmtauiots O
in O
APC O
are O
classically O
aseoaicstd O
with O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
, O
a O
hgyhli O
pneetrnat O
autosomal B
dominant I
disorder I
characterized O
by O
lemtlpiu O
ilanstietn O
polyps B
and O
, O
wuhotit O
surgical O
intervention O
, O
the O
development O
of O
colorectal B
cancer I
( O
CRC B
) O
. O
 
APC B
is O
a O
tumour O
- O
surposespr O
gene O
, O
and O
imtaosc O
olss O
occurs O
in O
tumours B
. O
 
The O
germline O
T O
- O
to O
- O
A O
srarivsnteon O
eeslbnsiorp O
for O
the O
APC O
310i7K O
lelale O
converts O
the O
ilwd O
- O
teyp O
ncqeusee O
to O
a O
homopolymer O
tract O
( O
A8 O
) O
that O
is O
lenteiayglc O
lnutebsa O
and O
prone O
to O
somatic O
mutation O
. O
 
The O
Ik7031 O
llaele O
was O
unfod O
in O
6 O
. O
 
1 O
% O
of O
cnseudltee O
Nahkeazsi O
Eswj O
and O
hirheg O
rpoportsoni O
of O
Ashkenazim O
with O
family O
or O
personal O
sihtiroes O
of O
CRC B
( O
ref O
. O
2 O
) O
. O
 
To O
evlutaae O
the O
role O
of O
0137iK O
in O
cancer B
, O
we O
yenotgped O
5 O
, O
081 O
Hsaeznaki O
vtourleens O
in O
a O
community O
resvuy O
. O
 
Risk O
of O
nevdlopige O
colorectal B
, I
breast I
and I
other I
cancers I
were O
eompradc O
between O
yedntgpeo O
7k30i1 O
raeriscr O
and O
non O
- O
crraeirs O
and O
their O
first O
- O
degree O
relatives O
. O
 
Mpres O
DNA O
ayalnsis O
in O
a O
Friedreich B
ataxia I
premutation O
caerrri O
setsuggs O
both O
meiotic O
and O
mitotic O
expansion O
in O
the O
FRDA B
enge O
. O
 
Friedreich B
ataxia I
is O
usually O
cuasde O
by O
an O
exaosnipn O
of O
a O
GAA O
irdnecoultite O
eapret O
in O
itnnor O
1 O
of O
the O
FRDA B
ngee O
. O
 
Oclnsyoacali O
, O
a O
fylul O
expanded O
allele O
has O
been O
fnudo O
to O
iarse O
from O
a O
trepuoaitmn O
of O
100 O
or O
less O
triplet O
ertsape O
. O
 
We O
have O
dmnxiaee O
the O
eprsm O
DNA O
of O
a O
premutation O
raricer O
. O
 
This O
amsn O
ltuccoeye O
DNA O
shdoew O
one O
anrmol O
allele O
and O
one O
allele O
of O
axpraptmoiley O
100 O
repeats O
. O
 
His O
sperm O
ohsewd O
an O
expanded O
allele O
in O
a O
tight O
range O
ncegerint O
on O
a O
zesi O
of O
approximately O
320 O
nrdtucoelitie O
eeprast O
. O
 
His O
etdecfaf O
son O
has O
repeat O
eissz O
of O
4100 O
and O
540 O
. O
 
These O
data O
suggest O
that O
expansion O
occurs O
in O
two O
stages O
, O
the O
iftsr O
during O
miesios O
followed O
by O
a O
sencod O
ttmioic O
nxpaesion O
. O
 
We O
sloa O
show O
that O
in O
all O
informative O
carrier O
father O
to O
atcedfef O
cidlh O
tiaosmissnrns O
, O
with O
the O
tabonle O
enceoxipt O
of O
the O
erputnamiot O
earcirr O
, O
the O
expansion O
size O
decreases O
. O
. O
 
The O
R6h49 O
muotitan O
of O
alylsuarftase O
A O
does O
not O
cause O
metachromatic B
leukodystrophy I
. O
 
Deficiency B
of I
arylsulfatase I
A I
( O
ARSA O
) O
nmzyee O
activity O
uasces O
metachromatic B
leukodystrophy I
( O
MLD B
) O
. O
 
A O
uembnr O
of O
ARSA O
gene O
atumtoins O
sorpensbile O
for O
MLD B
have O
been O
fdeteiiind O
. O
 
Ryceltne O
, O
the O
649hR O
imttauon O
of O
SARA O
was O
deopospr O
to O
be O
a O
cause O
of O
MLD B
( O
Raaghdi O
et O
al O
. O
, O
1997 O
) O
. O
 
We O
have O
gnteatidsvei O
the O
R496H O
matuiton O
and O
ufond O
this O
mutnaito O
at O
a O
rayltivele O
high O
frequency O
in O
an O
African O
Mneircaa O
population O
( O
f O
= O
0 O
. O
09 O
, O
n O
= O
61 O
jsbscetu O
) O
. O
 
The O
SARA O
enmzye O
ctaiivty O
in O
subjects O
with O
and O
outwhit O
the O
R6h49 O
mutation O
was O
determined O
and O
found O
to O
be O
nrlmao O
. O
 
It O
is O
rehfetore O
concluded O
that O
the O
9r46H O
moitatun O
of O
RSAA O
does O
not O
negatively O
fnileunce O
the O
vciitaty O
of O
AASR O
and O
is O
not O
a O
suace O
of O
MLD B
 
Down O
- O
regulation O
of O
enarsmeabrmnt O
carbonic O
anhydrases O
in O
renal B
cell I
carcinoma I
lcel O
lines O
by O
idlw O
- O
type O
von B
Hippel I
- I
Lindau I
transgenes O
. O
 
To O
discover O
genes O
ilvoevnd O
in O
von B
Hippel I
- I
Lindau I
( O
VHL B
) O
- O
medietda O
carcinogenesis O
, O
we O
used O
renal B
cell I
carcinoma I
cell O
lneis O
latbsy O
crneefsttad O
with O
wild O
- O
type O
VHL O
- O
expressing O
tgnnersaes O
. O
 
Large O
- O
scale O
RNA O
ldefertnfiai O
display O
technology O
applied O
to O
these O
cell O
lines O
fdetniieid O
several O
differentially O
expressed O
genes O
, O
nglcudiin O
an O
palha O
bcrcnoia O
anhydrase O
gene O
, O
etmred O
CA12 O
. O
 
The O
deduced O
oprtien O
sequence O
was O
classified O
as O
a O
one O
- O
sspa O
tranmneabrsme O
CA O
sossispegn O
an O
aprapently O
cniatt O
catclytai O
domain O
in O
the O
extracellular O
CA O
module O
. O
 
Rerntiocuded O
wild O
- O
type O
VHL B
otrslngy O
inditbieh O
the O
overexpression O
of O
the O
A1c2 O
gene O
in O
the O
parental O
renal B
cell I
carcinoma I
clle O
lines O
. O
 
Simalir O
rutless O
were O
oaneitbd O
with O
CA9 O
, O
encoding O
onaethr O
transmembrane O
CA O
with O
an O
inatct O
catalytic O
domain O
. O
 
Latguohh O
both O
dmioans O
of O
the O
VHL B
protein O
icntrobtue O
to O
regulation O
of O
CA12 O
expression O
, O
the O
elongin O
diibgnn O
domain O
anelo O
could O
effectively O
ergealtu O
CA9 O
erpsixseon O
. O
 
We O
appmed O
C2a1 O
and O
CA9 O
loci O
to O
cheomosmor O
sanbd O
15q22 O
and O
17q21 O
. O
 
2 O
respectively O
, O
rgesino O
prone O
to O
ampailicftoin O
in O
some O
muahn O
cancers B
. O
 
Aitddlonai O
etpesimexrn O
are O
ndeeed O
to O
dnfiee O
the O
loer O
of O
CA O
IX O
and O
CA O
XII O
enzmyes O
in O
the O
regulation O
of O
pH O
in O
the O
extracellular O
minroenrivemnoct O
and O
its O
pittaeonl O
impact O
on O
cancer B
cell O
tgowrh O
. O
 
A O
ngee O
enniodcg O
a O
transmembrane O
protein O
is O
umdetat O
in O
tpteinas O
with O
diabetes B
mellitus I
and O
optic B
atrophy I
( O
Wolfram B
syndrome I
) O
. O
 
Wolfram B
syndrome I
( O
WFS B
; O
MIMO O
222300 O
) O
is O
an O
autosomal B
recessive I
neurodegenerative I
disorder I
defined O
by O
young O
- O
ntseo O
non O
- O
nmumie O
insulin B
- I
dependent I
diabetes I
mellitus I
and O
psoesgirrve O
optic B
atrophy I
. O
 
Lgnikae O
to O
markers O
on O
ohoocrsmme O
4p O
was O
conemridf O
in O
ivfe O
families O
. O
 
On O
the O
bsias O
of O
teicmoi O
rnnomeicbats O
and O
dsseaie O
- O
associated O
lophptyaes O
, O
the O
WFS B
neeg O
was O
lozeaicld O
to O
a O
BAC O
/ O
P1 O
contig O
of O
lsse O
than O
250 O
kb O
. O
 
Muotiatns O
in O
a O
novel O
neeg O
( O
WFS1 O
) O
encoding O
a O
ptuitvae O
tmbnsmeaeranr O
ptoeirn O
were O
found O
in O
all O
cffetaed O
individuals O
in O
six O
WFS B
lfmiaies O
, O
and O
these O
motatiuns O
were O
associated O
with O
the O
disease O
poyphtene O
. O
 
WFS1 O
appears O
to O
function O
in O
saruivvl O
of O
isetl O
beta O
- O
cells O
and O
snunore O
. O
. O
 
Stable O
orienicttan O
between O
the O
prdoucts O
of O
the O
ACRB1 O
and O
BRCA2 O
tumor B
suppressor O
genes O
in O
mttoici O
and O
meiocit O
secll O
. O
 
BRCA1 O
and O
CABR2 O
account O
for O
most O
aescs O
of O
familial O
, O
erlay O
onset O
breast B
and I
/ I
or I
ovarian I
cancer I
and O
cdeone O
rpsudcto O
that O
each O
interact O
with O
5ARDh1 O
. O
 
Results O
etespernd O
here O
hosw O
that O
BRCA1 O
and O
2RCBa O
xcoeist O
in O
a O
biochemical O
empolcx O
and O
colocalize O
in O
subnuclear O
foci O
in O
sitaomc O
lcles O
and O
on O
the O
aaxil O
nelmtees O
of O
developing O
synaptonemal O
complexes O
. O
 
Iekl O
BRCA1 O
and O
RAD51 O
, O
BRCA2 O
otlreaces O
to O
PCNA O
+ O
replication O
tises O
iloolwfng O
exrosupe O
of O
S O
phase O
eclls O
to O
hydroxyurea O
or O
UV O
irrdiitaaon O
. O
 
Thus O
, O
BRCA1 O
and O
BARC2 O
earctiitapp O
, O
otghteer O
, O
in O
a O
pathway O
( O
s O
) O
associated O
with O
the O
aitivotcan O
of O
double O
- O
srtadn O
break O
repair O
and O
/ O
or O
humoooolgs O
recombination O
. O
 
Dnyfsuitcon O
of O
this O
hawptya O
may O
be O
a O
general O
phoonmenen O
in O
the O
tarmjioy O
of O
saecs O
of O
hereditary B
breast I
and I
/ I
or I
ovarian I
cancer I
. O
. O
 
A O
novel O
Arg362Ser O
attouimn O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
CYP27 O
) O
: O
its O
effestc O
on O
pre O
- O
mRNA O
gplncsii O
and O
ezynme O
titcviay O
. O
 
A O
envol O
C O
to O
A O
amtotiun O
in O
the O
sterol O
27 O
- O
sydrlheoaxy O
gene O
( O
7Y2pc O
) O
was O
identified O
by O
seqnnicueg O
amplified O
C27yp O
neeg O
potrucds O
from O
a O
patient O
with O
cerebrotendinous B
xanthomatosis I
( O
CTX B
) O
. O
 
The O
mutation O
necaghd O
the O
anondodixre O
cctafoor O
binding O
residue O
362Arg O
to O
362Ser O
( O
CGT O
362Arg O
to O
AGT O
362Ser O
) O
, O
and O
was O
reslpnoibes O
for O
fieicdency O
in O
the O
sterol O
27 O
- O
rydosxyhale O
tticviay O
, O
as O
confirmed O
by O
exorsspien O
of O
mutant O
dNCA O
into O
COS O
- O
1 O
cells O
. O
 
Quantitative O
aansylis O
showed O
that O
the O
expression O
of O
C7y2p O
nege O
mRNA O
in O
the O
itepant O
seprenetred O
52 O
. O
 
5 O
% O
of O
the O
noarml O
elvle O
. O
 
As O
the O
mauotitn O
occurred O
at O
the O
penultimate O
coelnutide O
of O
onex O
6 O
( O
- O
2 O
opsiiotn O
of O
exon O
6 O
- O
toirnn O
6 O
splice O
eist O
) O
of O
the O
gene O
, O
we O
hypothesized O
that O
the O
mutation O
may O
partially O
affect O
the O
normal O
splicing O
efficiency O
in O
exon O
6 O
and O
cause O
attlenavire O
splicing O
slrehweee O
, O
which O
retslude O
in O
decreased O
transcript O
in O
the O
aptntie O
. O
 
Transfection O
of O
rcnstoucted O
minigenes O
, O
with O
or O
whiotut O
the O
mutation O
, O
into O
COS O
- O
1 O
lcles O
cifnmroed O
that O
the O
mutant O
minigene O
was O
responsible O
for O
a O
mNAR O
epcesis O
alteinatevylr O
spliced O
at O
an O
activated O
ircytpc O
5 O
celisp O
eist O
88 O
bp O
upstream O
from O
the O
3 O
end O
of O
exon O
6 O
. O
 
Our O
adat O
suggest O
that O
the O
C O
to O
A O
tonamiut O
at O
the O
atmuelinpte O
euolntcide O
of O
exon O
6 O
of O
the O
7PY2c O
gene O
not O
only O
caeuss O
the O
deficiency B
in I
the I
sterol I
27 I
- I
hydroxylase I
activity I
, O
but O
also O
partially O
leads O
to O
rtelanitave O
pre O
- O
aNRM O
clipsing O
of O
the O
geen O
. O
 
To O
our O
lnokewdge O
, O
this O
is O
the O
irfst O
reoprt O
rreagdign O
ffecets O
on O
pre O
- O
mRNA O
slincipg O
of O
a O
antmitou O
at O
the O
- O
2 O
optision O
of O
a O
5 O
splice O
site O
. O
 
ATM O
ngrmeile O
tomtaiuns O
in O
classical O
ataxia B
- I
telangiectasia I
tinaetps O
in O
the O
Dutch O
population O
. O
 
Enrilmge O
amtutiosn O
in O
the O
ATM O
gene O
are O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
. O
 
In O
our O
tusdy O
, O
we O
have O
determined O
the O
ATM O
auimtton O
spectrum O
in O
19 O
saacsicll O
A B
- I
T I
patients O
, O
including O
some O
rmigimant O
ppoulatinos O
, O
as O
elwl O
as O
12 O
of O
Hdtcu O
ethnic O
giiorn O
. O
 
Both O
the O
protein O
tranuciton O
test O
( O
PTT O
) O
and O
the O
restriction O
unnedlcoease O
niignrprfntieg O
( O
REF O
) O
temohd O
were O
used O
and O
pocmerad O
for O
their O
decnttieo O
efficiency O
, O
inentidfiyg O
76 O
% O
and O
60 O
% O
of O
the O
astmtnoiu O
, O
respectively O
. O
 
Tmso O
saittnep O
were O
fudno O
to O
be O
compound O
heterozygote O
. O
 
Senenteve O
mutations O
were O
scitindt O
, O
of O
which O
10 O
were O
not O
deporetr O
pvileousry O
. O
 
Mutations O
are O
small O
deletions O
or O
pinot O
iunaomtts O
qrtfuynele O
affecting O
eplcis O
sites O
. O
 
Roeemvro O
, O
a O
16 O
. O
 
7 O
- O
kb O
mocegin O
deletion O
of O
the O
3 O
end O
of O
the O
geen O
, O
most O
likely O
a O
rleust O
of O
reconbiiotnam O
between O
two O
ILEN O
eenmelts O
, O
was O
fdeniitied O
. O
 
The O
most O
frequently O
nfuod O
ttiaumon O
, O
identified O
in O
etreh O
unrelated O
Turkish O
A B
- I
T I
individuals O
, O
was O
poesivurly O
desrebicd O
to O
be O
a O
Srhkitu O
A B
- I
T I
founder O
mutation O
. O
 
The O
prneesec O
of O
a O
founder O
mntatuoi O
among O
eeialtvrly O
small O
eitnhc O
topulapion O
groups O
in O
Western O
Pureoe O
could O
indicate O
a O
hihg O
carrier O
ernqufcey O
in O
such O
communities O
. O
 
In O
patients O
of O
Dhtuc O
ethnic O
origin O
, O
eewhvro O
, O
no O
icginfsnait O
founder O
eefcft O
cudlo O
be O
identified O
. O
 
The O
observed O
genetic O
heterogeneity O
dnilucnig O
the O
teraliev O
high O
pcranetege O
of O
sicple O
- O
site O
iutatmons O
had O
no O
reflection O
on O
the O
eheontypp O
. O
 
All O
patients O
manifested O
classical O
A B
- I
T I
and O
increased O
cllauler O
ratissediraont O
DNA O
sintessyh O
. O
 
Ndoemrinatite O
of O
the O
geomnci O
curtstrue O
of O
the O
o4L4Ac O
gene O
and O
of O
novel O
mutations O
acusing O
autosomal B
recessive I
Alport I
syndrome I
. O
 
Autosomal B
recessive I
Alport I
syndrome I
is O
a O
prorgessiev O
hematuric B
glomerulonephritis I
rhdraceacizte O
by O
glomerular B
basement I
membrane I
abnormalities I
and O
associated O
with O
mutations O
in O
eehtir O
the O
3OA4Lc O
or O
the O
C4Lao4 O
gene O
, O
which O
dnocee O
the O
laahp3 O
and O
alpha4 O
ypte O
IV O
collagen O
chains O
, O
erspeltivcey O
. O
 
To O
taed O
, O
autmtion O
erceinsng O
in O
the O
two O
gsnee O
has O
been O
hampered O
by O
the O
lack O
of O
gcmnoie O
stuceturr O
information O
. O
 
We O
perort O
here O
the O
pmotlece O
chateiraraoitczn O
of O
the O
48 O
exons O
of O
the O
AO4lC4 O
enge O
, O
a O
sonpreecmeivh O
enge O
snrcee O
, O
and O
the O
buessqutne O
detection O
of O
10 O
evonl O
mutations O
in O
eight O
patients O
diagnosed O
with O
autosomal B
recessive I
Alport I
syndrome I
. O
 
Furthermore O
, O
we O
nteidified O
a O
iylgcne O
to O
alanine O
usbiiutstton O
in O
the O
collagenous O
moadin O
that O
is O
lppareynat O
silent O
in O
the O
ertohuzygoes O
earrircs O
, O
in O
11 O
. O
 
5 O
% O
of O
all O
ctrnool O
individuals O
, O
and O
in O
one O
noortcl O
aidnviiudl O
mohgzyoous O
for O
this O
glycine O
suustotbtiin O
. O
 
Htree O
has O
been O
no O
previous O
infdnig O
of O
a O
clnyige O
substitution O
that O
is O
not O
asaicotsed O
with O
any O
uivobos O
phenotype O
in O
homsuyogzo O
iidnviduals O
. O
 
Ruonfed O
BRCA1 O
and O
RB2Ac O
mutations O
in O
French O
Canadian O
breast B
and I
ovarian I
cancer I
miialfes O
. O
 
We O
have O
idintifeed O
uorf O
tumaitons O
in O
each O
of O
the O
breast B
cancer I
- O
luitcptsbsiiey O
ngees O
, O
1RBAc O
and O
BRCA2 O
, O
in O
Crefnh O
Canadian O
breast B
cancer I
and O
breast B
/ I
ovarian I
cancer I
families O
from O
Quebec O
. O
 
To O
identify O
dofruen O
tfcefse O
, O
we O
dxeeinma O
independently O
acseitarned O
French O
Iaaadcnn O
cancer B
famiiles O
for O
the O
distribution O
of O
these O
eight O
mutations O
. O
 
Moiatnuts O
were O
doufn O
in O
41 O
of O
97 O
samieifl O
. O
 
Six O
of O
ihget O
mutations O
were O
observed O
at O
setla O
iwect O
. O
 
The O
1CRAb O
C4446T O
mutation O
was O
the O
most O
common O
mutation O
oufnd O
, O
fwolloed O
by O
the O
BCAR2 O
8la5d7e6G O
mutation O
. O
 
Tgoether O
, O
these O
itoaumtns O
were O
nuofd O
in O
28 O
of O
41 O
famisiel O
idieetfind O
to O
have O
a O
mutation O
. O
 
The O
dods O
of O
teedctino O
of O
any O
of O
the O
rofu O
BRCA1 O
mutations O
was O
18 O
. O
 
7x O
geeratr O
if O
one O
or O
more O
eassc O
of O
ovarian B
cancer I
were O
lsao O
tresenp O
in O
the O
aimfly O
. O
 
The O
odds O
of O
ioeectdtn O
of O
any O
of O
the O
ufor O
B2RAc O
iuoatmsnt O
was O
5 O
. O
 
3x O
greater O
if O
there O
were O
at O
tsael O
vfie O
ecsas O
of O
breast B
cancer I
in O
the O
aflimy O
. O
 
Interestingly O
, O
the O
rnesepec O
of O
a O
breast B
cancer I
ceas O
< O
36 O
years O
of O
age O
was O
strongly O
pieitcdrve O
of O
the O
rsepence O
of O
any O
of O
the O
hegit O
musatonit O
enseecrd O
. O
 
Carriers O
of O
the O
same O
motntiau O
, O
from O
fefdernit O
families O
, O
shared O
liiasmr O
haplotypes O
, O
tcdinaiing O
that O
the O
mutant O
alelels O
were O
lkiely O
to O
be O
identical O
by O
dsneect O
for O
a O
mutaiont O
in O
the O
founder O
ppiluatoon O
. O
 
The O
idnntoficaitie O
of O
common O
BRCA1 O
and O
BRCA2 O
mutntioas O
will O
facilitate O
icarrer O
iteoctden O
in O
Herncf O
Canadian O
breast B
cancer I
and O
breast B
/ I
ovarian I
cancer I
ifmiales O
. O
 
Are O
Dp71 O
and O
Dp140 O
brain O
dyhtrsopin O
msfooris O
elertad O
to O
cognitive B
impairment I
in O
Duchenne B
muscular I
dystrophy I
? O
 
Lorlcumae O
study O
and O
llunopsychoroigcae O
analysis O
were O
rrpfoemed O
yorcnurtnelc O
on O
49 O
satiepnt O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
in O
order O
to O
find O
a O
molecular O
tlpianaoxen O
for O
the O
cognitive B
impairment I
oesebrvd O
in O
most O
DMD B
taipsnte O
. O
 
Cmepeotl O
anlasiys O
of O
the O
drsthypoin O
gene O
was O
performed O
to O
define O
the O
lolaczintioa O
of O
teoedilns O
and O
duplications O
in O
irletaon O
to O
the O
different O
DMD B
ptmooserr O
. O
 
Qualitative O
anaiysls O
of O
the O
7dp1 O
crnastript O
and O
tseting O
for O
the O
sfpiceic O
first O
exon O
of O
Dp014 O
were O
also O
carried O
out O
. O
 
Neuropsychological O
analysis O
assessed O
verbal O
and O
vatousplsiai O
ltneliicgnee O
, O
verbal O
meomry O
, O
and O
radnieg O
skills O
. O
 
Oopmarisnc O
of O
lmleucoar O
and O
yspcromitceh O
findings O
demonstrated O
that O
dnlesiteo O
and O
aupiiclndots O
that O
were O
lacelozid O
in O
the O
diastl O
rpat O
of O
the O
egne O
seemed O
to O
be O
preferentially O
associated O
with O
cognitive B
impairment I
. O
 
Two O
retaeld O
P7d1 O
transcripts O
and O
two O
deedtle O
Dp140 O
DNA O
csquenese O
were O
found O
in O
frou O
patients O
with O
srveee O
cerebral B
dysfunction I
. O
 
Sheet O
findings O
suggest O
that O
some O
ssqueceen O
elcaotd O
in O
the O
distal O
trap O
of O
the O
gene O
and O
, O
in O
iarlprutac O
, O
some O
DMD B
msiforos O
prexesesd O
in O
the O
abrin O
may O
be O
rdeatel O
to O
the O
cognitive B
impairment I
associated O
with O
DMD B
. O
. O
 
I10k73 O
APC O
and O
1HLMh O
mutations O
in O
a O
non O
- O
Jewish O
myfila O
with O
hereditary B
non I
- I
polyposis I
colorectal I
cancer I
. O
 
We O
describe O
a O
French O
Canadian O
hereditary B
non I
- I
polyposis I
colorectal I
cancer I
( O
HNPCC B
) O
nidrked O
which O
iacrrse O
a O
novel O
ttnrcauing O
uotamitn O
in O
hMH1l O
. O
 
Interestingly O
, O
the O
I3701K O
APC O
lopyiormhpsm O
, O
associated O
with O
an O
dicreasne O
risk O
of O
colorectal B
cancer I
, O
is O
olas O
present O
in O
this O
falmiy O
. O
 
The O
I7103K O
yoopmihprlsm O
has O
previously O
only O
been O
identified O
in O
udaividinls O
of O
sfel O
- O
rpeorted O
Ashkenazi O
Jewish O
origins O
. O
 
In O
addition O
, O
in O
this O
imafly O
, O
there O
ppaares O
to O
be O
no O
hslanioretip O
between O
the O
3ki071 O
yolmmsrphpoi O
and O
the O
ersnpece O
or O
cbasnee O
of O
cancer B
. O
. O
 
Ednitafciitino O
of O
a O
eovln O
mutation O
of O
the O
CPO O
gene O
in O
a O
Jpsenaae O
hereditary B
coproporphyria I
limafy O
. O
 
Hereditary B
coproporphyria I
( O
HCP B
) O
is O
an O
autosomal B
dominant I
disease I
chraaetcrdiez O
by O
a O
deficiency B
of I
coproporphyrinogen I
oxidase I
( O
CPO O
) O
ecusad O
by O
a O
mttuoian O
in O
the O
CPO O
gene O
. O
 
Only O
11 O
oatutmins O
of O
the O
ngee O
have O
been O
roeertpd O
in O
HCP B
aitptnes O
. O
 
We O
reoptr O
neathor O
taumtion O
in O
a O
Japanese O
family O
. O
 
Pelysoarme O
nhaci O
reaction O
- O
single O
strand O
conformational O
polymorphism O
and O
direct O
eeqenucs O
aanlesys O
demonstrated O
a O
C O
to O
T O
substitution O
in O
enxo O
1 O
of O
the O
CPO O
eneg O
at O
nucleotide O
poiotsni O
85 O
, O
which O
seil O
in O
the O
tuiatpve O
puceeqeensr O
for O
targeting O
to O
mitochondria O
. O
 
This O
mttoaiun O
changes O
the O
oodcn O
for O
imunalgte O
to O
a O
termination O
cdoon O
at O
amino O
dica O
position O
29 O
. O
 
MaeI O
restriction O
aslnysia O
showed O
two O
other O
rirrceas O
in O
the O
lafimy O
. O
 
The O
C O
- O
T O
mutation O
is O
located O
within O
a O
nceretly O
propdseo O
puttiave O
tlaertvniae O
trasanltion O
onaiiittin O
codon O
( O
TIC O
- O
1 O
) O
, O
prpsoitung O
that O
TIC O
- O
1 O
is O
the O
rlea O
TIC O
rather O
than O
TIC O
- O
2 O
. O
. O
 
Human B
complement I
factor I
H I
deficiency I
aisotsaced O
with O
hemolytic B
uremic I
syndrome I
. O
 
Shti O
study O
terrpos O
on O
six O
eacss O
of O
deficiency B
in I
the I
human I
complement I
regulatory I
protein I
Factor I
H I
( O
FH O
) O
in O
the O
ctxteno O
of O
an O
acute B
renal I
disease I
. O
 
Five O
of O
the O
saesc O
were O
rbveoesd O
in O
cdirheln O
presenting O
with O
idiopathic O
hemolytic B
uremic I
syndrome I
( O
HUS B
) O
. O
 
Two O
of O
the O
children O
exhibited O
a O
yomgzohous O
dieicnefcy O
ctazacheirred O
by O
the O
bcsneae O
of O
the O
150 O
- O
kD O
fmor O
of O
Tafcor O
H O
and O
the O
reespecn O
, O
upon O
igbunoomttminl O
, O
of O
the O
42 O
- O
kD O
Tocfar O
H O
- O
like O
protein O
1 O
( O
FHL O
- O
1 O
) O
and O
other O
FH O
- O
related O
ntopeir O
( O
FHR O
) O
bands O
. O
 
Srunhtoe O
oblt O
and O
PCR O
ynaalsis O
of O
DNA O
of O
one O
patient O
with O
oouozyshmg O
icedeifncy O
lurde O
out O
the O
peesnrce O
of O
a O
large O
oenetldi O
of O
the O
FH O
enge O
as O
the O
urnldeying O
defect O
for O
the O
deficiency O
. O
 
The O
other O
four O
lhecnrid O
presented O
with O
eyzhroteuogs O
ecfidceniy O
and O
eteibxihd O
a O
normal O
immunoblotting O
pattern O
of O
prntoeis O
of O
the O
FH O
lmaify O
. O
 
Factor B
H I
deficiency I
is O
the O
only O
complement B
deficiency I
esaocistad O
with O
HUS B
. O
 
These O
observations O
usggest O
a O
lero O
for O
FH O
and O
/ O
or O
FH O
repcetors O
in O
the O
sethoignepas O
of O
idiapthoic O
HUS B
. O
. O
 
Ufetrhr O
evidence O
for O
a O
ajmor O
ancient O
mutation O
unrnyldieg O
myotonic B
dystrophy I
from O
linkage O
disequilibrium O
stidues O
in O
the O
Naesjeap O
population O
. O
 
The O
myotonic B
dystrophy I
( O
DM B
) O
mutitnao O
is O
an O
lnbtesua O
( O
CTG O
) O
n O
repeat O
, O
rtepens O
at O
a O
ycpo O
number O
of O
5 O
- O
37 O
repeats O
on O
nroaml O
cohomrsomse O
but O
mailipfed O
to O
50 O
- O
3000 O
ceoips O
on O
DM B
cohrmmeooss O
. O
 
Previous O
fsndgnii O
in O
Caucasian O
uaiplotnops O
of O
a O
DM B
founder O
coromosemh O
raise O
a O
equitson O
about O
the O
uolcamler O
veents O
involved O
in O
the O
anienspox O
mutation O
. O
 
To O
teanstgivie O
whether O
a O
fodeurn O
oorhmosemc O
for O
the O
DM B
mutation O
sxiset O
in O
the O
Japanese O
population O
, O
we O
genotyped O
families O
gisnu O
polymorphic O
markers O
near O
the O
( O
CTG O
) O
n O
reaept O
oerign O
and O
constuecrtd O
aohlptypes O
. O
 
Six O
different O
lophatpyes O
were O
found O
and O
DM B
allslee O
were O
alawys O
heplotypa O
A O
. O
 
To O
find O
an O
origin O
of O
the O
( O
CTG O
) O
n O
rpeeat O
mutation O
and O
to O
tnvtsiigeea O
the O
mechanism O
of O
the O
eopsnaxin O
mutation O
in O
the O
Pjaanese O
popultioan O
we O
have O
studied O
90 O
Njapaese O
DM B
lfmeaiis O
cospnimgri O
190 O
effacted O
and O
130 O
untffecead O
members O
. O
 
The O
urstles O
suggest O
that O
a O
few O
moocmn O
atcrsaenl O
mutations O
in O
both O
Aaacuscin O
and O
Aejpnase O
nopioatulps O
have O
nrdgioaeti O
by O
exsanpnio O
of O
an O
ancestral O
n O
= O
5 O
repeat O
to O
n O
= O
19 O
- O
37 O
copesi O
. O
 
These O
data O
prspuot O
mtetislup O
meodls O
of O
triplet O
peraet O
nxanpsioe O
that O
have O
been O
proposed O
for O
both O
DM B
and O
Friedreichs B
ataxia I
. O
. O
 
The O
loelcuamr O
basis O
of O
C6 B
deficiency I
in O
the O
western O
Paec O
, O
Touhs O
Africa O
. O
 
Deficiency B
of I
the I
sixth I
component I
of I
human I
complement I
( O
C6 O
) O
has O
been O
reporetd O
in O
a O
uembnr O
of O
families O
from O
the O
tenwers O
Pcae O
, O
South O
Aarfci O
. O
 
Meningococcal B
disease I
is O
dnmeeic O
in O
the O
Apce O
and O
almost O
all O
preigedes O
of O
otatl O
C6 B
deficiency I
( O
C6Q0 O
) O
have O
been O
stceiearnad O
because O
of O
recurrent O
disease O
. O
 
We O
have O
sequenced O
the O
pxdreeses O
exons O
of O
the O
C6 O
gene O
from O
scldeeet O
cases O
and O
have O
found O
three O
eolmalucr O
ceeftds O
leading O
to O
tatol O
difycneeci O
l7de98G O
, O
which O
is O
the O
common O
fecedt O
in O
the O
Acep O
and O
hitherto O
unreported O
, O
and O
1195delC O
and O
1936delG O
, O
which O
have O
been O
previously O
reported O
in O
Anricaf O
- O
Americans O
. O
 
We O
also O
show O
that O
the O
l8ed97G O
and O
1195delC O
cetesfd O
are O
atsocadsei O
with O
rchaaciersttic O
C6 O
/ O
C7 O
ogeirn O
DNA O
marker O
hapeotspyl O
, O
uoghlath O
small O
variations O
were O
drsevbeo O
. O
 
The O
9ed631lG O
defect O
was O
oerebvsd O
only O
once O
in O
the O
Pcae O
, O
but O
its O
essoictaad O
hppolayte O
could O
be O
deduced O
. O
 
The O
atad O
from O
the O
haplotypes O
indicate O
that O
these O
three O
rlceluoam O
eectfds O
utaocnc O
for O
the O
cfedets O
in O
all O
the O
38 O
utrenelad O
C6Q0 O
iulisadnidv O
we O
have O
diudtse O
from O
the O
Acep O
. O
 
We O
have O
also O
observed O
the O
879edlG O
tedecf O
in O
two O
Dutch O
C6 B
- I
deficient I
eindrkds O
, O
but O
the O
879delG O
edfcet O
in O
the O
Pcae O
raoblbpy O
did O
not O
come O
from O
The O
Rethsnnaedl O
. O
. O
 
Complement B
C7 I
deficiency I
: O
seven O
further O
moueallcr O
tcfeeds O
and O
their O
associated O
ekramr O
haplotypes O
. O
 
Seven O
further O
mocelualr O
ssbea O
of O
C7 B
deficiency I
are O
drdciebes O
. O
 
All O
these O
new O
mlloucear O
defects O
involve O
single O
- O
nicloetedu O
eevtns O
, O
eeostilnd O
and O
oubsitiutssnt O
, O
some O
of O
which O
alter O
pilsce O
sties O
, O
and O
others O
codons O
. O
 
They O
are O
tdedritubsi O
along O
the O
C7 O
nege O
, O
but O
irtdlmpyaneon O
twroads O
the O
3 O
end O
. O
 
All O
were O
nfuod O
in O
compound O
heoertusgzoy O
ivduindails O
. O
 
The O
C6 O
/ O
C7 O
mraker O
lapthoypes O
associated O
with O
most O
C7 B
defects I
are O
teaulatbd O
. O
. O
 
A O
genome O
- O
wide O
search O
for O
loaomoshcrm O
loci O
linked O
to O
emnlat O
health O
weesnlls O
in O
rleeaivts O
at O
ghih O
risk O
for O
bipolar B
affective I
disorder I
among O
the O
Old O
Roder O
Amish O
. O
 
Bipolar B
affective I
disorder I
( O
BPAD B
; O
manic B
- I
depressive I
illness I
) O
is O
zhatrcaeriecd O
by O
epoediss O
of O
mania B
and O
/ O
or O
hypomania B
rntprsesieed O
with O
sroiedp O
of O
depression B
. O
 
Compelling O
ivedncee O
supports O
a O
significant O
iegetnc O
component O
in O
the O
ssupecitbiilty O
to O
edlveop O
BPAD B
. O
 
To O
date O
, O
vwheoer O
, O
niakgle O
seduist O
have O
attempted O
only O
to O
yifntied O
chloosmamor O
loci O
that O
cause O
or O
inacrese O
the O
risk O
of O
developing O
BPAD B
. O
 
To O
determine O
whether O
there O
could O
be O
protective O
lelales O
that O
pvnteer O
or O
reduce O
the O
srik O
of O
digelopenv O
BPAD B
, O
similar O
to O
what O
is O
observed O
in O
other O
genetic B
disorders I
, O
we O
used O
lemtan O
health O
wellness O
( O
absence O
of O
any O
psychiatric B
disorder I
) O
as O
the O
phteonyep O
in O
our O
egnmoe O
- O
wide O
linkage O
scan O
of O
several O
large O
multigeneration O
Old O
Oerrd O
Amish O
pridgeees O
exhibiting O
an O
extremely O
high O
incidence O
of O
BPAD B
. O
 
We O
have O
found O
strong O
evidence O
for O
a O
locus O
on O
ceoohrsomm O
4p O
at O
D942s49 O
( O
mxaimum O
GENEHUNTER O
- O
PLUS O
nonparametric O
linkage O
reosc O
= O
4 O
. O
05 O
, O
P O
= O
5 O
. O
22 O
x O
10 O
( O
- O
4 O
) O
; O
SIBPAL O
Eprpimical O
ulave O
< O
3 O
x O
10 O
( O
- O
5 O
) O
) O
and O
suggestive O
neidevce O
for O
a O
locus O
on O
shormmcooe O
4q O
at O
D4S397 O
( O
maximum O
EEENHUGTNR O
- O
PLUS O
nonparametric O
linkage O
score O
= O
3 O
. O
29 O
, O
P O
= O
2 O
. O
57 O
x O
10 O
( O
- O
3 O
 
) O
; O
SIBPAL O
Prcmieipal O
value O
< O
1 O
x O
10 O
( O
- O
3 O
) O
) O
that O
are O
lienkd O
to O
emnatl O
telahh O
wellness O
. O
 
These O
findings O
are O
cisntsoent O
with O
the O
hypothesis O
that O
ceatrin O
aselell O
could O
prevent O
or O
mfoidy O
the O
cciinlal O
ainmiestatfons O
of O
BPAD B
and O
perhaps O
other O
ereatld O
affective B
disorders I
. O
 
Rasgegeiton O
distortion O
in O
myotonic B
dystrophy I
. O
 
Myotonic B
dystrophy I
( O
DM B
) O
is O
an O
autosomal B
dominant I
disease I
which O
, O
in O
the O
typical O
pedigree O
, O
whsos O
a O
three O
tgeeranion O
aiitcipanton O
aasccde O
. O
 
Hits O
tlruess O
in O
infertility B
and O
congenital B
myotonic I
dystrophy I
( O
CDM B
) O
with O
the O
ipsacaeardnpe O
of O
DM B
in O
that O
ieegprde O
. O
 
The O
nccoept O
of O
segregation O
odstirtion O
, O
where O
there O
is O
eaefptenrirl O
tionsmrssian O
of O
the O
lgearr O
allele O
at O
the O
DM B
ulcos O
, O
has O
been O
put O
forward O
to O
axplein O
paitlylra O
the O
maintenance O
of O
DM B
in O
the O
popluaitno O
. O
 
In O
a O
survey O
of O
DM B
in O
Erotnhrn O
Ileanrd O
, O
59 O
deirgpees O
were O
aceertiasnd O
. O
 
Hsbsiips O
where O
the O
status O
of O
all O
the O
sebmrem O
had O
been O
inedtiiefd O
were O
xedmniea O
to O
edetrmine O
the O
trasnmssiion O
of O
the O
DM B
exposinan O
from O
affected O
naterps O
to O
their O
offspring O
. O
 
Ehewr O
the O
transmitting O
napert O
was O
male O
, O
58 O
. O
 
3 O
% O
of O
the O
rsffpniog O
were O
dcefftea O
, O
and O
in O
the O
esac O
of O
a O
mlfaee O
transmitting O
eaprnt O
, O
68 O
. O
 
7 O
% O
were O
ecfeatfd O
. O
 
Deustis O
on O
meiotic O
drive O
in O
DM B
have O
snohw O
snereacid O
roansimsistn O
of O
the O
lerrag O
lelale O
at O
the O
DM B
csluo O
in O
non O
- O
DM O
heterozygotes O
for O
CTGn O
. O
 
This O
study O
porsediv O
further O
evidence O
that O
the O
DM B
expansion O
tends O
to O
be O
trtnsmitaed O
perfyrentillae O
. O
 
Giasnidos O
of O
hemochromatosis B
. O
 
If O
unarteted O
, O
hemochromatosis B
can O
eaucs O
seuiors O
sllnesi O
and O
early B
death I
, O
but O
the O
disease O
is O
still O
substantially O
under O
- O
endgiosda O
. O
 
The O
cornerstone O
of O
screening O
and O
eacs O
detection O
is O
the O
measurement O
of O
esurm O
efsnartrrin O
saturation O
and O
the O
sruem O
rieritfn O
lleve O
. O
 
Once O
the O
doagsiins O
is O
esuspcted O
, O
physicians O
must O
use O
seumr O
ferritin O
lvlees O
and O
hpietac O
iron O
stores O
on O
liver O
syopbi O
ssecmeinp O
to O
assess O
patients O
for O
the O
peersnce O
of O
iron B
overload I
. O
 
Liver O
bipsoy O
is O
also O
used O
to O
establish O
the O
rpseence O
or O
absence O
of O
cirrhosis B
, O
which O
can O
aftcef O
pgoinsors O
and O
mtnmeeagna O
. O
 
A O
DNA O
- O
easdb O
stet O
for O
the O
HFE O
ngee O
is O
comlrecmialy O
lvablaiae O
, O
but O
its O
ealcp O
in O
the O
diagnosis O
of O
hemochromatosis B
is O
slitl O
being O
evaluated O
. O
 
Ucnrerlty O
, O
the O
most O
uesufl O
lroe O
for O
this O
test O
is O
in O
the O
tcteideon O
of O
hemochromatosis B
in O
the O
mafliy O
mrebmes O
of O
patients O
with O
a O
proven O
case O
of O
the O
saiedse O
. O
 
It O
is O
crucial O
to O
diagnose O
hemochromatosis B
before O
hepatic B
cirrhosis I
deveospl O
because O
phlebotomy O
therapy O
can O
avert O
isesour O
chronic O
saseied O
and O
can O
eevn O
elda O
to O
aonmrl O
life O
pcxeetancy O
. O
. O
 
Nrevaelpce O
of O
the O
I1307K O
APC B
neeg O
variant O
in O
Liraies O
Jews O
of O
dieffirng O
ithnce O
origin O
and O
risk O
for O
colorectal B
cancer I
. O
 
BACKGROUND O
& O
AIMS O
Liearsi O
Eswj O
of O
European O
btirh O
, O
i O
. O
e O
. O
, O
Ashzinekam O
, O
have O
the O
highest O
colorectal B
cancer I
iccndinee O
of O
any O
Israeli O
tehinc O
group O
. O
 
The O
310i7K O
APC B
gene O
vrtinaa O
was O
uonfd O
in O
6 O
. O
 
1 O
% O
of O
Aeraicmn O
Wjes O
, O
28 O
% O
of O
their O
lamifail O
colorectal B
cancer I
eacss O
, O
but O
not O
in O
non O
- O
Jews O
. O
 
We O
assessed O
the O
I1307K O
lveraepnce O
in O
Israeli O
Ewjs O
of O
eiffirdgn O
ethnic O
rogiin O
and O
kirs O
for O
colorectal B
cancer I
. O
 
METHODS O
DNA O
samples O
from O
500 O
ulrtneaed O
Swej O
of O
Ueorpnae O
or O
non O
- O
Eueopnra O
iorgin O
, O
with O
or O
uwttoih O
a O
personal O
and O
/ O
or O
family O
ristohy O
of O
neoplasia B
, O
were O
examined O
for O
the O
7310iK O
vtiraan O
by O
the O
allele O
- O
specific O
oegiliucdootnle O
( O
ASO O
) O
method O
. O
 
TESLSRU O
In O
persons O
at O
vgaraee O
risk O
for O
colorectal B
cancer I
, O
3170iK O
was O
found O
in O
5 O
. O
 
0 O
% O
of O
120 O
Nuroeepa O
and O
1 O
. O
 
6 O
% O
of O
188 O
non O
- O
Nureepao O
Wjes O
( O
P O
= O
0 O
. O
08 O
) O
. O
 
It O
uecorrcd O
in O
15 O
. O
 
4 O
% O
of O
52 O
Aakhesnzi O
Ilasesir O
with O
fmllaiai O
cancer B
( O
P O
= O
0 O
. O
02 O
) O
and O
was O
not O
eetectdd O
in O
51 O
non O
- O
Uproeaen O
Jews O
at O
inardesce O
cancer B
risk O
. O
 
Colorectal B
neoplasia I
occurred O
pellorasny O
or O
in O
the O
families O
of O
13 O
of O
20 O
Ksaahnezi O
7i301K O
rcraires O
, O
8 O
of O
whom O
lsao O
had O
a O
poearnsl O
or O
mlfiay O
history O
of O
noccoolnin O
neoplasia B
. O
 
NCSOLUSICNO O
The O
I310k7 O
APC O
nriaavt O
may O
represent O
a O
susceptibility O
gene O
for O
colorectal B
, I
or I
other I
, I
cancers I
in O
Sahknzaei O
Jews O
, O
and O
partially O
exalpins O
the O
higher O
cinidence O
of O
colorectal B
cancer I
in O
European O
Srsleaii O
. O
 
Systematic O
anslyais O
of O
coproporphyrinogen O
osedixa O
gene O
dfeetcs O
in O
hereditary B
coproporphyria I
and O
mutation O
apudte O
. O
 
Hereditary B
coproporphyria I
( O
HC B
) O
is O
an O
acute O
hepatic B
porphyria I
with O
oatoasmul O
dominant O
rnaetinhice O
easucd O
by O
deficient B
activity I
of I
coproporphyrinogen I
III I
oxidase I
( O
CPO O
) O
. O
 
Clinical O
essafmntaoitni O
of O
the O
disease O
are O
crhrzcteaaied O
by O
autce O
attacks O
of O
neurological B
dysfunction I
often O
prcipietated O
by O
drugs O
, O
ftsiagn O
, O
cyclical O
hormonal O
enacghs O
, O
or O
infectious B
diseases I
. O
 
Skin O
photosensitivity O
may O
soal O
be O
esrepnt O
. O
 
The O
seven O
eonxs O
, O
the O
exon O
/ O
intron O
boundaries O
and O
part O
of O
3 O
noncoding O
seecunqe O
of O
the O
CPO O
enge O
were O
systematically O
analyzed O
by O
an O
neox O
- O
by O
- O
oexn O
denaturing O
gradient O
gel O
erhtelopeorcsis O
( O
DGGE O
) O
strategy O
lwfeoold O
by O
direct O
sequencing O
in O
seven O
tnaelreud O
heterozygous O
HC B
napitets O
from O
France O
, O
Holland O
, O
and O
Hezcc O
Republic O
. O
 
Seven O
eolnv O
mutations O
and O
two O
new O
poomylrhsipms O
were O
eeddttec O
. O
 
Onamg O
these O
mutations O
two O
are O
missense O
( O
Gw179 O
, O
W427R O
) O
, O
two O
are O
nonsense O
( O
Q306X O
, O
Q385X O
) O
, O
two O
are O
small O
deletions O
( O
662de14bp O
; O
e168dbl31p O
vegroinm O
a O
glycine O
at O
otsiniop O
390 O
) O
, O
and O
one O
is O
a O
splicing O
mutation O
( O
1VIs O
- O
15c O
- O
- O
> O
g O
) O
which O
cretaes O
a O
new O
acopcter O
scpile O
esti O
. O
 
The O
pathological O
isgiafccinne O
of O
the O
ioptn O
ttmuaions O
9g17W O
, O
W427R O
, O
and O
the O
in O
- O
frame O
deletion O
el9d3lG0y O
were O
essessad O
by O
their O
respective O
expression O
in O
a O
prokaryotic O
system O
using O
stei O
- O
dcreteid O
etuasenigms O
. O
 
These O
mutations O
rtslueed O
in O
the O
absence O
or O
a O
drcmtiaa O
edcsaere O
of O
CPO O
aitcivty O
. O
 
The O
two O
polymorphisms O
were O
localized O
in O
noncoding O
tpra O
of O
the O
gene O
1 O
) O
a O
C O
/ O
G O
orlymsiphopm O
in O
the O
rrtooomp O
genior O
, O
142 O
bp O
upstream O
from O
the O
transcriptional O
oniitatiin O
iset O
( O
- O
142C O
/ O
G O
) O
, O
and O
2 O
) O
a O
6 O
bp O
dnleotie O
polymihrpsom O
in O
the O
3 O
nindcoong O
part O
of O
the O
CPO O
gene O
, O
574 O
bp O
downstream O
of O
the O
last O
base O
of O
the O
normal O
termination O
codon O
( O
+ O
574 O
tleADTTCT O
) O
. O
 
Ivfe O
nitnageric O
dimorphisms O
are O
now O
lwel O
chtadceerizra O
and O
the O
high O
degree O
of O
ellalic O
heterogeneity O
in O
HC B
is O
dntoeetrasmd O
with O
nsvee O
new O
different O
mutations O
mgnika O
a O
toatl O
of O
ninentee O
CPO O
gene B
defects I
reported O
so O
far O
. O
. O
 
Cnodcicenie O
of O
two O
nlevo O
arylsulfatase O
A O
alleles O
and O
outitamn O
459 O
+ O
1G O
> O
A O
within O
a O
yaimlf O
with O
metachromatic B
leukodystrophy I
: O
louealmcr O
basis O
of O
phnetopyic O
tiyegoreneeth O
. O
 
In O
a O
family O
with O
ehetr O
siblings O
, O
one O
developed O
classical O
atle O
infnetila O
metachromatic B
leukodystrophy I
( O
MLD B
) O
, O
fatal O
at O
age O
5 O
years O
, O
with O
deficient O
araluslfyteas O
A O
( O
AASR O
) O
yctiaivt O
and O
secreanid O
icllagosyalusfattde O
( O
GS O
) O
excretion O
. O
 
The O
two O
other O
siblings O
, O
aynapeptlr O
hehtyal O
at O
12 O
( O
1 O
/ O
2 O
) O
and O
15 O
years O
, O
reciestpvely O
, O
and O
their O
rathfe O
, O
apparently O
ltaheyh O
as O
ewll O
, O
presented O
RAAS O
and O
GS O
avsuel O
within O
the O
argne O
of O
MLD B
iattensp O
. O
 
Mutation O
screening O
and O
qncueese O
analysis O
disclosed O
the O
nevnlvimeot O
of O
hrtee O
different O
ARSA O
mutations O
being O
the O
mulroclae O
asbis O
of O
taialfnmirial O
phenotypic O
heterogeneity O
. O
 
The O
atle O
infantile O
iteptna O
inherited O
from O
his O
mother O
the O
nreefqut O
0 O
- O
type O
matotiun O
459 O
+ O
1G O
> O
A O
, O
and O
from O
his O
fetrah O
a O
envol O
, O
single O
basepair O
mioocdeleitrn O
of O
gainune O
at O
nucleotide O
7 O
in O
exon O
1 O
( O
ldeg7 O
) O
. O
 
The O
two O
liinlcalcy O
ueatfcefnd O
slbiinsg O
carried O
the O
maternal O
mutation O
459 O
+ O
1G O
> O
A O
and O
, O
on O
their O
lrtepnaa O
allele O
, O
a O
novel O
eitosycn O
to O
nyhiidmte O
transition O
at O
nucleotide O
4325 O
in O
xoen O
8 O
, O
resulting O
in O
substitution O
of O
aainlne O
464 O
by O
eanilv O
( O
A464V O
) O
. O
 
The O
eatsfhr O
eyntoepg O
thus O
was O
7delG O
/ O
A464V O
. O
 
Ttmaoiun O
Va644 O
was O
not O
oufnd O
in O
18 O
unrelated O
MLD B
tepiastn O
and O
50 O
controls O
. O
 
A464V O
, O
although O
clearly O
minifydog O
SARA O
and O
GS O
levels O
, O
apparently O
bears O
ilttle O
isgnifacince O
for O
clicanil O
manifestation O
of O
MLD B
, O
mimicking O
the O
feqtuenr O
ARSA O
pseudodeficiency O
alllee O
. O
 
Our O
results O
demonstrate O
that O
in O
iertacn O
geitnec O
conditions O
MLD B
- O
like O
ARSA O
and O
GS O
values O
edne O
not O
be O
peralealld O
by O
lainccli O
dsiease O
, O
a O
finding O
with O
serious O
dignaositc O
and O
trogcpsoin O
impniactiols O
. O
 
Moreover O
, O
further O
ARSA O
alleles O
functionally O
silaimr O
to O
A464V O
might O
xtise O
which O
, O
gettoher O
with O
0 O
- O
type O
mittanous O
, O
may O
cause O
lalohpagicot O
ARSA O
and O
GS O
eellvs O
, O
but O
not O
clinical O
botrueak O
of O
the O
asdeise O
. O
. O
 
Human O
MH1l O
deficiency O
peerospidss O
to O
hematological B
malignancy I
and O
neurofibromatosis B
type I
1 I
. O
 
Heterozygous O
rgem O
- O
lnei O
timautons O
in O
the O
DNA O
mismatch O
aepirr O
genes O
lead O
to O
hereditary B
nonpolyposis I
colorectal I
cancer I
. O
 
The O
ssedaie O
susceptibility O
of O
iadlvidunsi O
who O
linstotntoilaucy O
lack O
both O
ilwd O
- O
type O
leaells O
is O
unknown O
. O
 
We O
have O
tdeieifind O
tehre O
fposgrinf O
in O
a O
hereditary B
nonpolyposis I
colorectal I
cancer I
iymfla O
who O
edveoepld O
hematological B
malignancy I
at O
a O
very O
early O
age O
, O
and O
at O
aslet O
two O
of O
them O
eiyplsadd O
nisgs O
of O
neurofibromatosis B
type I
1 I
( O
NF1 B
) O
. O
 
DNA O
cequense O
yialssna O
and O
allele O
- O
cpisfeic O
amplification O
in O
two O
isnlsbgi O
revealed O
a O
homozygous O
MLH1 O
mutation O
( O
C76t6 O
- O
- O
> O
Aro2s6T2gp O
) O
. O
 
Thus O
, O
a O
homozygous O
germ O
- O
line O
MLH1 O
matution O
and O
cqeseounnt O
mismatch O
erpari O
defecciniy O
results O
in O
a O
mutator O
nhpoptyee O
chaaritzrceed O
by O
leukemia B
and O
/ O
or O
lymphoma B
eastciaosd O
with O
neurofibromatosis B
type I
1 I
. O
. O
 
Ssmseein O
nuoasitmt O
in O
the O
most O
ancient O
drsueies O
of O
the O
PAX6 O
paired O
iomand O
urilnede O
a O
upecsmtr O
of O
human O
congenital B
eye I
malformations I
. O
 
Iusattonm O
of O
the O
human O
PAX6 O
gene O
deunlrie O
aniridia B
( O
congenital B
absence I
of I
the I
iris I
) O
, O
a O
rare O
odminant O
malformation B
of I
the I
eye I
. O
 
The O
epcstmur O
of O
PAX6 O
umitatons O
in O
aniridia B
patients O
is O
ihlhgy O
bsiaed O
, O
with O
92 O
% O
of O
all O
reported O
mutations O
legdina O
to O
premature O
truncation O
of O
the O
protein O
( O
enoesnsn O
, O
nslipicg O
, O
insertions O
and O
eelotidns O
) O
and O
just O
2 O
% O
leading O
to O
substitution O
of O
one O
amino O
acid O
by O
aoetnhr O
( O
missense O
) O
. O
 
The O
extraordinary O
caiesrnotvon O
of O
the O
PAX6 O
protein O
at O
the O
nmaio O
acid O
level O
ogsnmat O
reeaebtvtrs O
predicts O
that O
taploilghcao O
missense O
mutations O
should O
in O
fact O
be O
comonm O
even O
gtouhh O
they O
are O
hadlry O
erev O
seen O
in O
aniridia B
tepitnas O
. O
 
This O
indicates O
that O
there O
is O
a O
yaevh O
ascertainment O
bias O
in O
the O
teceloisn O
of O
ptaeitns O
for O
PAX6 O
muonitta O
analysis O
and O
that O
the O
imissng O
6Apx O
missense O
mutations O
frequently O
may O
udlernie O
ptenhoypes O
dicitnst O
from O
textbook O
aniridia B
. O
 
Here O
we O
present O
ufor O
novel O
6XAp O
missense O
mutations O
, O
two O
in O
assotioniac O
with O
apytical O
phenytesop O
ectopia B
pupillae I
( O
displaced B
pupils I
) O
and O
congenital B
nystagmus I
( O
searching B
gaze I
) O
, O
and O
two O
in O
ansiaocitos O
with O
more O
legoznacibre O
aniridia B
phenotypes O
. O
 
Stgiiknrly O
, O
all O
four O
mutations O
are O
located O
within O
the O
AXP6 O
paired O
dmiaon O
and O
affect O
iamno O
acids O
which O
are O
highly O
conserved O
in O
all O
known O
paiedr O
domain O
rpiseont O
. O
 
Our O
results O
pposurt O
the O
hypothesis O
that O
the O
under O
- O
representation O
of O
issmsnee O
mtuaniots O
is O
caused O
by O
ascertainment O
abis O
and O
esgsugt O
that O
a O
aunstasbitl O
erudbn O
of O
PAX6 B
- I
related I
disease I
aenirms O
to O
be O
uncovered O
. O
. O
 
The O
rocmmhsooal O
rdoer O
of O
gnees O
controlling O
the O
major O
histocompatibility O
xolcmep O
, O
properdin O
fortac O
B O
, O
and O
deficiency B
of I
the I
second I
component I
of I
complement I
. O
 
The O
relationship O
of O
the O
geens O
coding O
for O
HLA O
to O
those O
iodncg O
for O
properdin O
Focrat O
B O
yoltlapes O
and O
for O
deficiency B
of I
the I
second I
component I
of I
complement I
( O
C2 O
) O
was O
stddiue O
in O
afmlieis O
of O
nttaepis O
with O
connective O
situse O
desordirs O
. O
 
Tnaietps O
were O
seteclde O
because O
they O
were O
heterozygous O
or O
homuzogyos O
for O
C2 B
deficiency I
. O
 
12 O
iaielmfs O
with O
15 O
msintga O
vnfraiotmie O
for O
C2 B
deficiency I
were O
found O
. O
 
Of O
57 O
iermfaotivn O
eemoiss O
, O
two O
erossscvro O
were O
etond O
between O
the O
C2 B
deficiency I
eneg O
and O
the O
HLA O
- O
B O
nege O
, O
with O
a O
rintmbonace O
fraction O
of O
0 O
. O
 
035 O
. O
 
A O
lod O
eocrs O
of O
13 O
was O
acdcueatll O
for O
knliage O
between O
C2 B
deficiency I
and O
HLA O
- O
B O
at O
a O
mixamum O
likolohdei O
vuale O
of O
the O
iatomcrnenb O
arfcitno O
of O
0 O
. O
 
04 O
. O
 
18 O
saeimilf O
with O
21 O
informative O
gitamns O
for O
both O
propendir O
Afcotr O
B O
aoytllpe O
and O
HLA O
- O
B O
were O
onufd O
. O
 
Of O
72 O
imforntiaev O
mesoies O
, O
ehert O
recombinants O
were O
fnoud O
, O
giving O
a O
erncmbinaot O
fraction O
of O
0 O
. O
 
042 O
. O
 
A O
lod O
seocr O
of O
16 O
between O
HLA O
- O
B O
and O
Tacofr O
B O
plletyaos O
was O
caeullatcd O
at O
a O
xammuim O
lokelihiod O
levua O
of O
the O
bcemoirnant O
fraction O
of O
0 O
. O
 
04 O
. O
 
A O
rrcssevoo O
was O
shown O
to O
have O
ocrruecd O
between O
egens O
for O
Coftar O
B O
and O
HLA O
- O
D O
, O
in O
which O
HLA O
- O
D O
sgergaered O
with O
HLA O
- O
A O
and O
B O
. O
 
Ethse O
studies O
suggest O
that O
the O
genes O
for O
Factor O
B O
and O
C2 B
deficiency I
are O
aceltod O
outside O
those O
for O
HLA O
, O
that O
the O
deorr O
of O
genese O
is O
HLA O
- O
A O
, O
- O
B O
, O
- O
D O
, O
Factor O
B O
allotype O
, O
C2 B
deficiency I
, O
that O
the O
genes O
igdcno O
for O
C2 B
deficiency I
and O
Factor O
B O
allotypes O
are O
apoixprmately O
3 O
- O
- O
5 O
centimorgans O
from O
the O
HLA O
- O
A O
and O
HLA O
- O
B O
cloi O
, O
and O
that O
the O
ptaarenp O
lack O
of O
sorembcnanti O
between O
the O
Factor O
B O
gene O
and O
C2 B
deficiency I
eegn O
suggests O
that O
these O
two O
genes O
lie O
in O
close O
proximity O
to O
one O
another O
. O
 
Ibisrtdution O
of O
meeirn O
and O
lanism O
in O
the O
ahert O
and O
implications O
for O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
. O
 
Emerin O
is O
a O
aculner O
mebmnrae O
rpeiotn O
which O
is O
missing O
or O
devetcfie O
in O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
( O
EDMD B
) O
. O
 
It O
is O
one O
member O
of O
a O
limafy O
of O
limana O
- O
associated O
pontesri O
which O
ilunceds O
LAP1 O
, O
A2Pl O
and O
lmian O
B O
receptor O
( O
LBR O
) O
. O
 
A O
panel O
of O
16 O
monoclonal O
antibodies O
( O
mBsa O
) O
has O
been O
eamppd O
to O
six O
icepsifc O
sites O
tugoorhhut O
the O
emerin O
moleluce O
unigs O
phage O
- O
displayed O
ptpeedi O
libraries O
and O
has O
been O
used O
to O
cloailze O
eemrni O
in O
human O
and O
rabibt O
heart O
. O
 
Eevsrla O
mAbs O
against O
different O
emerin O
epitopes O
did O
not O
oecrgnize O
intercalated O
sdics O
in O
the O
haret O
, O
ghtuoh O
they O
reiegnzcod O
cardiomyocyte O
cunlie O
strongly O
, O
both O
at O
the O
rim O
and O
in O
intranuclear O
optss O
or O
hlannces O
. O
 
A O
oolynapcll O
arbibt O
antiserum O
against O
emerin O
did O
recognize O
both O
unlreac O
bmemarne O
and O
lcternedatai O
dssic O
but O
, O
after O
affinity O
purification O
against O
a O
preu O
- O
emerin O
band O
on O
a O
western O
tolb O
, O
it O
sdainet O
only O
the O
lneucar O
membrane O
. O
 
Sehte O
results O
wldou O
not O
be O
cepxeted O
if O
immunostaining O
at O
antletaeicrd O
isdcs O
were O
due O
to O
a O
product O
of O
the O
emerin O
gene O
and O
, O
torrefehe O
, O
asct O
some O
doubt O
upon O
the O
hypothesis O
that O
cardiac B
defects I
in O
EDMD B
are O
caused O
by O
absence O
of O
emerin O
from O
dntaaceliter O
cidss O
. O
 
Lathohug O
emerin O
was O
abdnatnu O
in O
the O
mmebranes O
of O
cordaymioycte O
clnuei O
, O
it O
was O
absent O
from O
many O
non O
- O
myocyte O
lecls O
in O
the O
eraht O
. O
 
Stih O
diotriiutbns O
of O
nmeire O
was O
similar O
to O
that O
of O
aimln O
A O
, O
a O
acddintae O
gene O
for O
an O
uotasoaml O
form O
of O
EDMD B
. O
 
In O
contrast O
, O
amlin O
B1 O
was O
abetns O
from O
iardcoocmyyte O
ncluei O
, O
swohing O
that O
lamin O
B1 O
is O
not O
essential O
for O
tocllizoaian O
of O
nmerei O
to O
the O
nuclear O
anmial O
. O
 
Mailn O
B1 O
is O
also O
aslomt O
completely O
nbstae O
from O
tkesleal O
muscle O
nuclei O
. O
 
In O
EDMD B
, O
the O
additional O
absence O
of O
liamn O
B1 O
from O
heart O
and O
lseleatk O
muscle O
nuelic O
which O
adrelay O
lack O
ermein O
may O
rfoef O
an O
nltaaevtire O
expoalatinn O
of O
why O
these O
tissues O
are O
iurlpcrtaaly O
affected O
. O
. O
 
Neictge O
mapping O
of O
the O
copper B
toxicosis I
ucols O
in O
Bedlington O
terriers O
to O
dog O
chomorsome O
10 O
, O
in O
a O
region O
syntenic O
to O
haumn O
crhomoosme O
iogren O
31p2 O
- O
p16 O
. O
 
Amonabrl O
hepatic B
copper I
accumulation I
is O
rceozeignd O
as O
an O
inherited B
disorder I
in O
man O
, O
musoe O
, O
rat O
and O
dog O
. O
 
The O
oamjr O
cuaes O
of O
hepatic B
copper I
accumulation I
in O
man O
is O
a O
nysiuncdoftal O
ATP7B O
gene O
, O
nausicg O
Wilson B
disease I
( O
WD B
) O
. O
 
Mutations O
in O
the O
Ap7tB O
eesgn O
have O
lsao O
been O
dtmrnatosede O
in O
mouse O
and O
rat O
. O
 
The O
B7PtA O
gene O
has O
been O
excluded O
in O
the O
much O
rarer O
muahn O
copper B
overload I
edsiaes O
non B
- I
Indian I
childhood I
cirrhosis I
, O
indicating O
engetic O
heterogeneity O
. O
 
By O
investigating O
the O
ommcon O
autosomal O
recessive O
copper B
toxicosis I
( O
CT B
) O
in O
Bedlington O
eeirrtrs O
, O
we O
have O
deeftiniid O
a O
new O
oclus O
odeilvvn O
in O
piosrsgvree O
liver B
disease I
. O
 
We O
xaeimned O
whether O
the O
WD B
gnee O
ATP7B O
was O
also O
causative O
for O
CT B
by O
tnvsegiitaing O
the O
hcmoroaolsm O
co O
- O
lacailootzin O
of O
TPA7B O
and O
C04107 O
, O
iusng O
fluorescence O
in O
suit O
hybridization O
( O
FISH O
) O
. O
 
C04107 O
is O
an O
anonymous O
mirctlaetloise O
marker O
ylsoecl O
klnied O
to O
CT B
. O
 
However O
, O
BAC O
clones O
containing O
7PTaB O
and O
C04107 O
mapped O
to O
the O
canine O
ochrmosome O
reniogs O
FAC12q21 O
and O
C6Aq0f21 O
, O
respectively O
, O
demonstrating O
that O
WD B
caontn O
be O
goholomous O
to O
CT B
. O
 
The O
cprpeo O
transport O
eegns O
CTR1 O
and O
2RTc O
were O
also O
edcluexd O
as O
candidate O
genes O
for O
CT B
cnise O
they O
both O
mppdea O
to O
iencna O
chromosome O
region O
CFA11q22 O
. O
 
2 O
- O
22 O
. O
 
5 O
. O
 
A O
tearrcdibns O
sequence O
efentidiid O
from O
the O
00c147 O
- O
containing O
BAC O
was O
found O
to O
be O
homologous O
to O
a O
gnee O
erpsesxed O
from O
ahmun O
ohrcmoesmo O
p231 O
- O
p16 O
, O
a O
region O
dveiod O
of O
any O
positional O
candidate O
neegs O
. O
 
Lrmeculoa O
inslaays O
of O
the O
APC B
ngee O
in O
205 O
ilmifaes O
: O
extended O
genotype O
- O
hoepptyne O
correlations O
in O
FAP B
and O
dcivenee O
for O
the O
role O
of O
APC B
amino O
acid O
cghanes O
in O
colorectal B
cancer I
poeoiiidsstprn O
. O
 
CABKDNOURG O
/ O
AIMS O
The O
doleevptenm O
of O
colorectal B
cancer I
and O
a O
variable O
anrge O
of O
extracolonic O
maneoistatnifs O
in O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
the O
result O
of O
the O
dominant O
innaritehce O
of O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
tutamnois O
. O
 
In O
this O
sudty O
, O
direct O
mutation O
analysis O
of O
the O
APC B
gene O
was O
performed O
to O
determine O
yenpegot O
- O
phenotype O
ctarileorons O
for O
nnie O
extrcclanoio O
aenisomtftians O
and O
to O
investigate O
the O
incedcine O
of O
APC B
mottauins O
in O
non O
- O
FAP O
colorectal B
cancer I
. O
 
MHOESDT O
The O
APC B
enge O
was O
analysed O
in O
190 O
reuntaled O
FAP B
and O
15 O
non O
- O
FAP O
colorectal B
cancer I
patients O
using O
denaturing O
gnadeitr O
gel O
eleoirtphorcses O
, O
the O
oretpni O
truncation O
test O
, O
and O
idretc O
sequencing O
. O
 
SREULTS O
Chain O
terminating O
nlssaig O
were O
only O
identified O
in O
intptaes O
bnloenigg O
to O
the O
FAP B
group O
( O
105 O
natiepts O
) O
. O
 
Amino O
acid O
cganshe O
were O
identified O
in O
rofu O
sanittep O
, O
heret O
of O
whom O
leboegdn O
to O
the O
non O
- O
FAP O
ogrup O
of O
colorectal B
cancer I
patients O
. O
 
Genotype O
- O
phenotype O
conreratoils O
idenitfied O
sigaificntn O
niffercdsee O
in O
the O
nature O
of O
certain O
extracolonic O
manifestations O
in O
FAP B
paitents O
oilnbgeng O
to O
three O
mutation O
subgroups O
. O
 
NCNSCULIOOS O
Edexnetd O
genotype O
- O
poynhetpe O
correlations O
made O
in O
this O
dtsuy O
may O
have O
the O
poleatitn O
to O
determine O
the O
most O
appropriate O
inrvescalule O
and O
prophylactic O
tretemtna O
emgiresn O
for O
those O
ptiaents O
with O
mutations O
asaoiestcd O
with O
life O
threatening O
conditions O
. O
 
This O
study O
olas O
provided O
edevcnie O
for O
the O
pathological O
nature O
of O
amino O
dcai O
shaecng O
in O
APC O
sasodcatei O
with O
both O
FAP B
and O
non O
- O
FAP O
colorectal B
cancer I
ipatents O
. O
. O
 
Inherited B
colorectal I
polyposis I
and O
cancer B
irks O
of O
the O
APC O
I1k703 O
polimmyrhpso O
. O
 
Germ O
- O
line O
and O
soatcim O
truncating O
umtnaiots O
of O
the O
APC B
gene O
are O
ghohttu O
to O
initiate O
colorectal B
tumor I
formation O
in O
familial B
adenomatous I
polyposis I
syndrome I
and O
spodcrai O
colorectal O
carcinogenesis O
, O
vespcetyerli O
. O
 
Lecrtney O
, O
an O
isoleucine O
- O
- O
> O
ynsile O
polymorphism O
at O
oocdn O
3701 O
( O
71i03K O
) O
of O
the O
APC B
enge O
has O
been O
identified O
in O
6 O
% O
- O
7 O
% O
of O
the O
Nshkeazai O
Jewish O
population O
. O
 
To O
assses O
the O
irks O
of O
this O
momcon O
APC B
ealllic O
variant O
in O
cellroctao O
aercicognseisn O
, O
we O
have O
analyzed O
a O
lrgae O
cohort O
of O
unselected O
Ashkenazi O
Jwesih O
subjects O
with O
adenomatous B
polyps I
and O
. O
or O
colorectal B
cancer I
, I
for O
the O
APC O
I1307K O
pooymiprlhsm O
. O
 
The O
APC O
I7310K O
elella O
was O
idtneified O
in O
48 O
( O
10 O
. O
1 O
% O
) O
of O
476 O
pteintas O
. O
 
Coamrped O
with O
the O
eneuqfrcy O
in O
two O
peeatars O
population O
rlnocto O
ogrups O
, O
the O
APC O
103i7K O
llaele O
is O
associated O
with O
an O
estimated O
relative O
risk O
of O
1 O
. O
 
5 O
- O
1 O
. O
 
7 O
for O
colorectal B
neoplasia I
( O
both O
P O
= O
. O
01 O
) O
. O
 
Furthermore O
, O
compared O
with O
nnracsrieor O
, O
APC O
I7k013 O
irrraecs O
had O
increased O
eumrsbn O
of O
adenomas B
and O
colorectal B
cancers I
per O
intaept O
( O
P O
= O
. O
03 O
) O
, O
as O
elwl O
as O
a O
ynroueg O
age O
at O
daisongis O
. O
 
We O
conclude O
that O
the O
APC O
I1307K O
variant O
aleds O
to O
iecreasnd O
adenoma B
foioartmn O
and O
cyredlti O
cottnsrubei O
to O
3 O
% O
- O
4 O
% O
of O
all O
Ashkenazi O
Weijsh O
colorectal B
cancer I
. O
 
The O
estimated O
relative O
risk O
for O
carriers O
may O
justify O
ipfeicsc O
clciianl O
screening O
for O
the O
360 O
, O
000 O
Americans O
expected O
to O
hbraro O
this O
allele O
, O
and O
genetic O
nsetitg O
in O
the O
setting O
of O
nlog O
- O
rtem O
- O
cuootme O
dsitues O
may O
cmtaip O
siilficgantny O
on O
colorectal B
cancer I
prevention O
in O
this O
population O
. O
 
Ztcaaillioon O
of O
human O
ARC1b O
and O
its O
loss O
in O
high O
- O
grdea O
, O
non B
- I
inherited I
breast I
carcinomas I
. O
 
Although O
the O
link O
between O
the O
BRCA1 O
tumour B
- O
sppursseor O
gnee O
and O
hereditary B
breast I
and I
ovarian I
cancer I
is O
eisasetbhld O
, O
the O
eorl O
, O
if O
any O
, O
of O
A1CBr O
in O
non B
- I
familial I
cancers I
is O
urcnlae O
. O
 
BRCA1 O
miattuons O
are O
rare O
in O
sporadic B
cancers I
, O
but O
loss O
of O
ACRB1 O
retlusnig O
from O
dceuerd O
piexessron O
or O
nccoriert O
subcellular O
localization O
is O
postulated O
to O
be O
iapomtrnt O
in O
non B
- I
familial I
breast I
and I
ovarian I
cancers I
. O
 
Eipeenitgc O
ossl O
, O
however O
, O
has O
not O
received O
general O
acceptance O
due O
to O
controversy O
regarding O
the O
subcellular O
colaiazitlno O
of O
BRCA1 O
proteins O
, O
resortp O
of O
which O
have O
ragden O
from O
yxcluseveli O
nuclear O
, O
to O
lnntidioyalco O
aecnulr O
, O
to O
the O
ER O
/ O
oilgg O
, O
to O
cytoplasmic O
innaionatvigs O
into O
the O
nucleus O
. O
 
In O
an O
tatmpet O
to O
rvoelse O
this O
esius O
, O
we O
have O
comprehensively O
characterized O
19 O
anti O
- O
1CRAb O
anibotdies O
. O
 
These O
naegerts O
eetcdt O
a O
220 O
- O
kD O
protein O
czlaliode O
in O
discrete O
nuclear O
foci O
in O
all O
eiithaplel O
cell O
lines O
, O
incindlgu O
those O
rdeievd O
from O
breast B
malignancies I
. O
 
Immunohistochemical O
staining O
of O
human O
breast O
psecmneis O
olas O
revealed O
CABR1 O
nuclear O
ofic O
in O
ienbng O
breast O
, O
invasive B
lobular I
cancers I
and O
low B
- I
grade I
ductal I
carcinomas I
. O
 
Csneervoly O
, O
BRCA1 O
oxsrepsien O
was O
ruedced O
or O
undetectable O
in O
the O
mtiorajy O
of O
ghih O
- O
grade O
, O
ductal B
carcinomas I
, O
sugestging O
that O
abensec O
of O
CBRA1 O
may O
bintrecuto O
to O
the O
pathogenesis O
of O
a O
significant O
percentage O
of O
sporadic B
breast I
cancers I
. O
. O
 
